Institution of Page Charges
Effective January 1, 1998, a page charge of $50 per printed page will be assessed for all manuscripts published in Clinical Cancer Research. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. In the event of any other source of grant or other support exists, when the other source of grant or other support exists, the author(s) may apply to Dr. Margaret Foit, Director of Publications, AACR Public Information Office, to waive the charge. Waivers are at the discretion of the Assistant Editor in Chief. At the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institution official. The page charges are to be paid for the page charges. 1999 Annual Meeting The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research. The next AACR Annual Meeting will take place in Philadelphia, PA, April 10–14, 1999. The Chairperson of this meeting is William E. Houghton of the University of Pennsylvania Cancer Center. Co-Chairpersons are Carol W. Greider, Johns Hopkins University School of Medicine; Joseph F. Fraumeni, Jr., National Cancer Institute; and Henry Fong Liu, Robert Wood Johnson Medical School. The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, scientific forums, and meet-the-expert sunrise sessions. It will also review paper submissions by members of the scientific community and will schedule a variety of sessions in minisymposia, poster discussion sessions, and poster sessions. The deadline for submission of abstracts will be November 6, 1998. Further program information can be found on the AACR’s Website (http://www.aacr.org). Call for Nominations for 1999 AACR-Pezzler International Award for Cancer Research The AACR-Pezzler International Award for Cancer Research in recognition of an annual award is made to a scientist engaged in cancer research, who is a resident of the United States, who has made important contributions to cancer research, and who is engaged in cancer research. The award is made at the discretion of the AACR-Pezzler International Award Committee and is awarded to the individual who is judged to have made the outstanding contribution to cancer research in the past year. The award is $10,000.00. The deadline for submission of nominations is December 15, 1998. The nomination form is available from the AACR-Pezzler International Award Committee, 666 Second Avenue, New York, NY 10010-2571. The deadline for submission of nominations is December 15, 1998. The nomination form is available from the AACR-Pezzler International Award Committee, 666 Second Avenue, New York, NY 10010-2571. The deadline for submission of nominations is December 15, 1998.

AACR Special Conference on Cancer Research A number of meetings are being organized in the AACR’s series of smaller scientific meetings. Following are some general guidelines for meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Non-members may receive this information after October 31, 1998, with names and addresses to: Meetings Listing, AACR, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR’s website (http://www.aacr.org). October 14–18, 1998 Gene Regulation and Cancer (10th Anniversary of AACR Special Conferences in Cancer Research) Chairpersons: PHILLIP A. SHARP, Cambridge, MA JAMES A. LEIDY, Cambridge, MA STEVEN L. MCKNIGHT, Dallas, TX The Homestead, Hot Springs, VA December 2–5, 1998 Research Approaches to the Prevention and Cure of Prostate Cancer Chairpersons: JONATHAN W. SIMONS, Baltimore, MD KENNETH J. PIENTA, Austin, TX Hyatt Grand Champions Resort, Indian Wells (Palm Springs), CA 1999 Molecular Determinants of Sensitivity to Antitumor Agents Chairpersons: MICHAEL J. KASTAN, Memphis, TN I. DAVID GOLDMAN, Bronx, NY Whistler Resort and Conference Centre, Whistler, B.C., Canada
Instructions for Authors

Scope

Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in Clinical Cancer Research, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator’s Institutional Review Board.

Review Process

The review process is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Publication Fees

A page charge of $50 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Procedures for Submission

Submit papers directly to the Deputy Editor or to one of the seven Senior Editors, each of whom is responsible for a particular area of research. The Deputy Editor and the Senior Editors will conduct the review process with the expert assistance of the journal’s Associate Editors, will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief, Deputy Editor, and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;

References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.
SAMPLE REFERENCES:

Figures
Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is $975 per color figure. Submit color figures on flexible backing.

Proofs
Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors’ corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

Typesetting Manuscripts from Computer Disks
Clinical Cancer Research requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

Research Areas of the Editor-in-Chief, Deputy Editor, and Senior Editors
John Mendelsohn, M.D., Editor-in-Chief
Department of Educational Publishing Services-227
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6014; Fax: (713) 792-6016
E-mail: jmendelsohn@notes.mdacc.tmc.edu

Waun Ki Hong, M.D., Deputy Editor
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Box 80
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6363; Fax: (713) 796-8655
E-mail: waun_hong@isqm.mda.uth.tmc.edu

Clinical trials targeted at specific malignancies, chemoprevention
Bruce A. Chabner, M.D.
Department of Hematology/Oncology
Massachusetts General Hospital
Cox Building, Room 640
100 Blossom Street
Boston, MA 02114
Phone: (617) 724-3200; Fax: (617) 724-3166
E-mail: chabner.bruc@mgh.harvard.edu

Clinical pharmacology and pharmacokinetics, drug metabolism, drug sensitivity and resistance, drug interactions
Michael B. Kastan, M.D., Ph.D.
Department of Hematology-Oncology
St. Jude Children’s Research Hospital
332 N. Lauderdale St.
Memphis, TN 38105-2794
Phone: (901) 495-3968; Fax: (901) 495-3966
E-mail: michael.kastan@stjude.org

Cell cycle regulation, cell death
Lance A. Liotta, M.D., Ph.D.
Laboratory of Pathology
National Cancer Institute
Building 10, Room 2A33
National Institutes of Health
10 Center Drive, MSC 1500
Bethesda, MD 20892-1500
Phone: (301) 496-3185; Fax: (301) 402-0043
E-mail: lance@helix.nih.gov

Pathology, metastasis
David Sidransky, M.D.
Otolaryngology/Head & Neck Cancer Research
Johns Hopkins University
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
Phone: (410) 550-5153; Fax: (410) 614-1411
E-mail: dsidrans@welchlink.welch.jhu.edu

Molecular pathogenesis, molecular correlates
Paul Sondel, M.D., Ph.D.
Departments of Pediatrics, Human Oncology, & Genetics
University of Wisconsin Clinical Science Center
K4/448
600 Highland Avenue
Madison, WI 53792
Phone: (608) 263-9069; Fax: (608) 263-4226
E-mail: psmondel@facstaff.wisc.edu

Immunotherapy and cytokines—preclinical, and clinical trials
Beverly A. Teicher, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center, DC 0540
Indianapolis, IN 46285
Phone: (317) 276-2739; Fax: (317) 277-3652
E-mail: teicher_beverly_a@lilly.com

Experimental therapeutics, preclinical pharmacology, combined modality regimens, animal therapy models
Jeffrey M. Trent, Ph.D.
Laboratory of Cancer Genetics
National Center for Human Genome Research
National Institutes of Health
Building 49, Room 4A22
49 Convent Drive, MSC 4470
Bethesda, MD 20892-4470
Phone: (301) 402-2023; Fax: (301) 402-2040
E-mail: jtrent@nchgr.nih.gov

Genetics, cytogenetics

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Scientific Publishing-227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6014; Fax: (713) 792-6016
or:
Publications Department, American Association for Cancer Research, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Phone: (215) 440-9300; Fax: (215) 440-9355.
90th Annual Meeting

American Association for Cancer Research

April 10-14, 1999
Philadelphia, Pennsylvania

The World's Top Multidisciplinary Program in The Cancer Field

Presenting The Most Up-To-Date Information in Basic, Translational, and Clinical Cancer Research

In This Booklet:
- Abstract Submission Forms and Instructions
- Program Information
- Information on Awards for Basic, Translational, and Clinical Investigators
- Registration and Housing Information
- AACR Membership Application Forms
SPECIAL EVENTS
(Topics with Confirmed Speakers/Organizers in Parentheses)

EDUCATIONAL SESSIONS AND METHODS WORKSHOPS
(SATURDAY AFTERNOON, APRIL 10, 1999)
To Be Announced

OFFICIAL OPENING EVENT
(SUNDAY MORNING, APRIL 11, 1999)
Presidential Address (Webster K. Cavenee)
Plenary Session: New Frontiers in Cancer Research (Waun Ki Hong)
Genetics (Robert A. Weinberg)
Immunology and Vaccines (Lloyd J. Old)
Therapeutics and Translational Research (Judah Folkman)
Hormonal Intervention and Prevention (C. Kent Osborne)
AACR-Pezcoller International Cancer Research Award Lecture
Special Lecture (James D. Watson)

SYMPOSIA
Drug Discovery: From Basic Science to the Clinic (Daniel D. Von Hoff)
Animal Models for Human Cancer: Recent Developments and New Challenges (Tyler Jacks)
Stem Cell Gene Therapy (Cynthia E. Dunbar)
Basic and Clinical Approaches to Lung Cancer (David P. Carbone)
Basic and Clinical Approaches to Ovarian Cancer (Robert C. Bast, Jr.)
Hormonally Related Tumors: Basic and Clinical Aspects
(Bert W. O'Malley and Marc E. Lippman)
Dendritic Cell Vaccines (Ronald Levy)
Topoisomerases in Carcinogenesis and Cancer Treatment (Leroy F. Liu)
Infectious Agents and Cancer (Nancy E. Mueller)
Advances in Chemoprevention (Raymond N. DuBois)
Diet and Cancer (John D. Potter)
Signal Transduction
Genomics, Genetics, and New Approaches to Cancer (Richard D. Klauber)
Confronting the Tobacco Epidemic (Virginia L. Ernst)
Apoptosis (Craig B. Thompson)
Telomeres, Centromeres, and Chromosomal Instability (Carol W. Greider)
Genetic Instability, DNA Damage, and Checkpoint Regulation
(Jeffrey Wahl)
 Invasion, Metastasis, and Angiogenesis (Isaiah J. Fidler)
DNA Repair
Ubiquitin and Protein Degradation (Alexander Varshavsky)
Gene-Environment and Gene-Gene Interactions (Kenneth Olden and Margaret R. Spitz)
Replication and the Cell Cycle (Jacqueline A. Lees)
Transcriptional Regulation and Cancer (Lorraine J. Gudas)
Drug Resistance and Cell Cycle Gene Abnormalities (Joseph R. Bertino)
Late-Breaking Science (Speakers To Be Selected Shortly Before the Meeting)

"MEET-THE-EXPERT" SUNRISE SESSIONS
Drug Resistance (Susan P. Cole)
Molecular Detection of Minimal Residual Disease (Theodore F. Zipf)
Cancer Screening (Barrett S. Kramer)
Microsatellite Instability
Design of Chemoprevention Trials (David S. Alberts)
Genetic Imprinting
Molecular Signaling of CML (Jean Y. J. Wang)
Cancer Metastasis: Cellular and Clinical Studies (David Tarin)
Embryonal Stem-Cell-based Technology (Randall S. Johnson)
bcl2: Its Family and Modification (Timothy J. McDonnell)
Apoptosis and Chemotherapy (John A. Hickman)
Caspases
Replicative Senescence (Judith Campisi)
DNA Damage and Checkpoint Control
Yeast Systems for Drug Discovery
Drug Design and Development (Randall K. Johnson)
In vivo Imaging of Gene Expression in Solid Tumors (Ralph Weissleder)
Molecular Cytogenetics (Joe W. Gray)
Genetic Determinants of Prostate Cancer
Chromatin
p53 Gene Therapy-mediated Radio/Chemosensitization (Esther H. Chang)
TGFB and Colon Cancer
Inherited Susceptibility to Breast and Ovarian Cancers (Funmi I. Olopade)
VEGF
Genetics of Multiple Endocrine Neoplasia II (MEN II) (Bruce A. J. Ponder)
Differentiation Therapy (Samuel Waxman)
Small Molecule Therapeutics
Molecular Processes in DNA Repair after Irradiation (Gloria C. Li)
Integration of Biological Agents into Chemotherapy
New Therapeutic Agents
AIDS-related Malignancies (Ellen Feigal)
Molecular Genetics of Colon Cancer
Behavioral Oncology (Barbara K. Rimer)
Mdm2 (Guillermina Lozano)
Origins of Melanoma (Margaret A. Tucker)
Natural Agents and Chemoprevention (Hirotaka Fujiki)
Tumor Vaccine Therapy (Michael T. Lotze)
Genetics of Wilms Tumor (Michael R. DeBaun)
Biology of Premalignant Lesions (Walter N. Hittelman)
Prospects for Biological Agents (Peter J. Houghton)
Antibodies as Chemotherapeutic Agents
Antisense Therapies (Stanley T. Crooke)
EGF Receptor Blockade (John Mendelsohn)

FORUMS
Tamoxifen: Risks and Benefits
Ethical and Legal Issues in Genetic Testing

PROGRAM COMMITTEE
Waun Ki Hong, Chairperson
Carol W. Greider, Co-Chairperson
Joseph F. Fraumeni, Jr., Co-Chairperson
Leroy F. Liu, Co-Chairperson

EDUCATION COMMITTEE
Jeffrey M. Trent, Chairperson

EXHIBITS COMMITTEE
David S. Alberts, Chairperson

LOCAL ARRANGEMENTS COMMITTEE
Robert F. Onslow, Chairperson

Further Information: AACR Office • Public Ledger Building, Suite 826 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483 • Telephone: 215-440-9300 • FAX: 215-440-9313 • E-mail: meetings@aacr.org • Website: http://www.aacr.org
1998-99 BOARD OF DIRECTORS

Webster K. Cavenee, President
Daniel D. Von Hoff, President-Elect
Bayard D. Clarkson, Treasurer
Donald S. Coffey, Past President
Karen S. H. Antman
J. Carl Barrett
William T. Beck
Susan P. C. Cole
O. Michael Colvin
Tom Curran
Eric R. Fearon
Stephen H. Friend
Waun Ki Hong
Lynn M. Matrisian
Joseph V. Simone
Jean Y. J. Wang

90TH ANNUAL MEETING COMMITTEES

PROGRAM COMMITTEE
Waun Ki Hong, Chairperson
Joseph F. Fraumeni, Jr., Co-Chairperson
Carol W. Greider, Co-Chairperson
Leroy F. Liu, Co-Chairperson
Members listed on page 33

EDUCATION COMMITTEE
Jeffrey M. Trent, Chairperson
Bruce A. Chabner
Susan F. C. Cole
Leland H. Hartwell
Michael B. Kastan
John M. Lehman
Diana M. Lopez
John D. Potter
Frank J. Rauscher, III
Marcel Rosenwieg
Joy C. Ware
Waun Ki Hong, Ex officio
Additional members to be appointed

EXHIBITS COMMITTEE
David S. Alberts, Chairperson
John E. Schurig, Jr.
Cheryl Lyn Walker
Additional members to be appointed

LOCAL ARRANGEMENTS COMMITTEE
Robert F. Ozols, Chairperson
Members to be appointed

TOPICS OF SPECIAL SESSIONS AT 1999 ANNUAL MEETING

LETTER FROM THE PROGRAM CHAIRPERSON, WAUN KI HONG
1999 ACR ANNUAL MEETING TENTATIVE SCHEDULE OF EVENTS
GENERAL INFORMATION
REGULATIONS APPLYING TO ABSTRACTS AND PROFFERED PAPERS
INSTRUCTIONS FOR THE PREPARATION AND MAILING OF ABSTRACTS
ABSTRACT CATEGORY/SUBCLASSIFICATION LIST
COPYRIGHT TRANSFER/CONFLICT OF INTEREST DISCLOSURE FORM
SAMPLE COMPLETED ABSTRACT
OFFICIAL ABSTRACT FORMS
MEMBERSHIP APPLICATION FORMS
Active and Corresponding
Associate
HOUSING INFORMATION
TRAVEL AWARDS AVAILABLE
FORTHCOMING ACR SCIENTIFIC CONFERENCES
ADVANCE REGISTRATION
Frequently Asked Questions
Registration Form
ANNUAL MEETING PROGRAM COMMITTEE MEMBERS

Be sure to fill out and return the acknowledgment card included with these instructions.
Dear Colleague:

We are very excited about the upcoming 1999 Annual Meeting Program and believe that once you have reviewed this Call for Abstracts, you will share our excitement. For the last five months I have been working along with the Program Committee Co-Chairpersons (Joe Fraumeni, Carol Greider, and Leroy Liu) and other members of the Committee to survey the entire field of cancer research and to identify both today's most rapidly developing research areas and the most appropriate scientists to organize the sessions in which these new data will be presented. We have made special efforts to ensure that the Program properly reflects the exciting progress in translational research that is taking place in many areas of the cancer field. A great deal of work still needs to be done on the Program, especially the review and scheduling of the important abstracts you will submit. However, if the progress made to date is any indication, the meeting in Philadelphia will be an outstanding one. We would like to highlight below some of the important features of the meeting and draw your attention to some of the important information in this booklet.

Symposia and "Meet-the-Expert" Sunrise Sessions. The list of special sessions on the inside front cover of this booklet shows the considerable progress we have already made on the major symposia and the "meet-the-expert" sunrise sessions to take place this April. We anticipate that all cancer researchers, regardless of their scientific specialties, will find a good number of these sessions of intense interest. Of course, this list becomes more complete almost daily as more scientists accept our invitations to organize these sessions. Please consult the Association's Website (http://www.aacr.org) for regular updates. We are very grateful to the nearly 50 Chairpersons of the various subcommittees of the Program Committee who made the initial suggestions from which the lists of symposia and sunrise sessions were developed. Clearly, without their insights and timely responses to our memoranda and questionnaires, the 1999 Program would not have been as comprehensive or exciting.

Opening Event. We would like to draw your particular attention to the Opening Event, "New Frontiers in Cancer Research," on Sunday morning, April 11. After Web Cavenee's Presidential Address, four outstanding scientists (Robert A. Weinberg, Lloyd J. Old, Judah Folkman, and C. Kent Osborne) will give overviews of the most important developments in their respective fields. This plenary session will be followed by the 1999 AACR-Pezcoller International Cancer Research Award Lecture and then finally by a new feature of the annual meeting, an inspiring Nobel Laureate Lecture. We are very pleased to announce that James D. Watson has agreed to present this talk.

Submission of Abstracts. The principal goal of this booklet is to give you the information you need to submit an abstract of your work for presentation at the meeting. We urge you to do so because your participation is essential to the meeting's goal of presenting all of the latest research findings in all of the subdisciplines of cancer research. The abstract categories and subcategories were reorganized last year to reflect new advances in the field. These should make it easier for you to categorize your work and ensure that it is reviewed by the most appropriate members of the Program Committee. Please review this list (Pages 10-12) and then carefully follow the instructions on Pages 5-9 as you prepare and submit your abstract.

Late-Breaking Sessions. Another innovation this year is the addition of a second session of late-breaking papers, one which consists of invited presentations. As the pace of scientific discovery accelerates, it is essential that we develop new procedures to ensure that our meeting presents the most up-to-date and novel information. This Fall and Winter, Web Cavenee, the Program Committee Co-Chairpersons (Joe Fraumeni, Carol Greider, and Leroy Liu), and I will be closely monitoring scientific developments and will then ask scientists doing particularly important new work to make presentations in a special symposium which Web and I will chair on Wednesday, April 14. The meeting will feature the session of proffered late-breaking papers that has become so popular since its inception in 1995. As you know, the latter session consists of important work completed after the abstract deadline of November 6, 1998; this event will take place late on Tuesday morning, April 13. If enough high-quality abstracts are received by this year's deadline (March 12, 1999), this session will again consist of both oral and poster presentations. You can contribute to the success of both of these sessions. If you are aware of particularly exciting new work that would be appropriate for the late-breaking symposium of invited speakers, please let us know about it. We anticipate issuing invitations to these speakers around January 15, 1999. Also, if you yourself make an important discovery after the November 6, 1998, deadline, be sure to submit an abstract for the late-breaking session of proffered papers by March 12.

Registration/Housing. Both the Local Arrangements Committee, which Bob Ozols is chairing, and the AACR Staff are looking forward to welcoming you to their home city. For the first time the AACR is offering a discounted, "early bird" registration rate (deadline of December 1, 1998). Many scientists make their decisions to attend the annual meeting well in advance, and we want to reward this loyalty with our new registration feature. See Page 31 for details.

Registrants may make hotel reservations via telephone, FAX, or the Internet. Complete instructions and information about participating hotels can be found on Pages 23-28. As we anticipate an even larger attendance than last year, the AACR has reserved over 1,000 more hotel rooms for the Philadelphia meeting than were reserved in New Orleans. About 3,000 of these rooms are within a 10-block radius of the Pennsylvania Convention Center (the site of scientific sessions), and all of them are less than a 30-minute drive from the Center. Complimentary shuttle buses will be provided between the Center and all meeting hotels except the Philadelphia Marriott, the Association's headquarters hotel. (The Marriott is connected to the Center.) You will see from the information provided that the majority of the hotels outside the vicinity of the Center are located at the Philadelphia airport for convenient arrivals and departures.

Summary. We hope you will consider this booklet to be your invitation to submit an abstract, register for the meeting, obtain a hotel room, and attend the 90th Annual Meeting of the AACR this April. If you are not already a member of the Association, please also consider submitting an application at this time so that you can enjoy all of the benefits of membership, including significantly reduced registration rates for this and other AACR scientific meetings. Established scientists will find the application for active or corresponding membership on Pages 19-20. The next deadline for submission is January 1, 1999. Graduate and medical students, postdoctoral fellows, and physicians in training will find the associate member application on Pages 21-22. Please note that these applications may be submitted at any time but must be received by February 15, 1999, to qualify for reduced registration rates.

With your participation the AACR Annual Meeting will continue to be the world's most important venue for the presentation of high-quality basic, translational, and clinical cancer research, the meeting that no cancer researcher can afford to miss. We look forward to seeing you in Philadelphia.

Very truly yours,

Waun Ki Hong, M.D.
1999 Program Committee Chairperson
<table>
<thead>
<tr>
<th>SATURDAY, APRIL 10</th>
<th>MONDAY, APRIL 12 (CONT.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.-2:00 p.m.</td>
<td>NCI Board of Scientific Advisors Session</td>
</tr>
<tr>
<td>9:30 a.m.-12:00 noon</td>
<td>1:00-2:15 p.m.</td>
</tr>
<tr>
<td>12:00 noon-2:00 p.m.</td>
<td>1:00-5:00 p.m.</td>
</tr>
<tr>
<td>2:00-6:00 p.m.</td>
<td>1:15-2:15 p.m.</td>
</tr>
<tr>
<td>2:15-4:15 p.m.</td>
<td>1:30-5:00 p.m.</td>
</tr>
<tr>
<td>4:30-6:30 p.m.</td>
<td>2:30-5:00 p.m.</td>
</tr>
<tr>
<td>6:30-8:30 p.m.</td>
<td>5:15-6:15 p.m.</td>
</tr>
<tr>
<td>8:00-10:00 p.m.</td>
<td>6:30-8:30 p.m.</td>
</tr>
<tr>
<td></td>
<td>NCI Training Branch Workshop</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SUNDAY, APRIL 11</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Meet-the-Expert Sunrise Sessions</td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>NIH Grants Session</td>
</tr>
<tr>
<td>8:00 a.m.-12:00 noon</td>
<td>Poster Sessions</td>
</tr>
<tr>
<td>8:00-9:00 a.m.</td>
<td>Presidential Address and Elion Award and Fellowship Presentations</td>
</tr>
<tr>
<td>9:00 a.m.-11:00 a.m.</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>11:00 a.m.-12:00 noon</td>
<td>AACR-Pezcoller Award Lecture</td>
</tr>
<tr>
<td>12:00 noon-1:00 p.m.</td>
<td>Nobel Laureate Lecture</td>
</tr>
<tr>
<td>12:00 noon-5:00 p.m.</td>
<td>Exhibit Show Open</td>
</tr>
<tr>
<td>1:15-5:15 p.m.</td>
<td>Poster and Poster Discussion Sessions</td>
</tr>
<tr>
<td>1:15-2:15 p.m.</td>
<td>Associate Member Business Meeting</td>
</tr>
<tr>
<td>1:30-5:00 p.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>2:15-4:45 p.m.</td>
<td>Symposia</td>
</tr>
<tr>
<td>5:00-6:00 p.m.</td>
<td>Clowes Award Lecture</td>
</tr>
<tr>
<td>6:30-8:30 p.m.</td>
<td>Minority Issues Committee Careers Symposium</td>
</tr>
<tr>
<td>9:00-11:30 p.m.</td>
<td>Annual Reception</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>MONDAY, APRIL 12</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Meet-the-Expert Sunrise Sessions</td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>WICR Mentoring Session</td>
</tr>
<tr>
<td>8:00-10:30 a.m.</td>
<td>Symposia</td>
</tr>
<tr>
<td>8:00 a.m.-12:00 noon</td>
<td>Poster and Poster Discussion Sessions</td>
</tr>
<tr>
<td>8:15-11:45 a.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>10:00 a.m.-4:00 p.m.</td>
<td>Rosenthal Award Lecture</td>
</tr>
<tr>
<td>10:45 a.m.-12:00 noon</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>12:00 noon-1:00 p.m.</td>
<td>Burchenal Award Lecture</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>TUESDAY, APRIL 13</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Meet-the-Expert Sunrise Sessions</td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Associate Member Sunrise Session</td>
</tr>
<tr>
<td>8:00-10:30 a.m.</td>
<td>Symposia</td>
</tr>
<tr>
<td>8:00 a.m.-12:00 noon</td>
<td>Poster and Poster Discussion Sessions</td>
</tr>
<tr>
<td>8:15-11:45 a.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>10:00 a.m.-4:00 p.m.</td>
<td>Rosenthal Award Lecture</td>
</tr>
<tr>
<td>10:45 a.m.-12:00 noon</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>12:00 noon-4:00 p.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>12:15-3:45 p.m.</td>
<td>Sympoisa</td>
</tr>
<tr>
<td>12:30-3:00 p.m.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>WEDNESDAY, APRIL 14</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Meet-the-Expert Sunrise Sessions</td>
</tr>
<tr>
<td>7:30-11:30 a.m.</td>
<td>Poster Discussion Sessions</td>
</tr>
<tr>
<td>8:00-10:30 a.m.</td>
<td>Late-Breaking Research Symposium</td>
</tr>
<tr>
<td>8:00 a.m.-12:00 noon</td>
<td>Poster Sessions</td>
</tr>
<tr>
<td>8:15-11:45 a.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>9:00 a.m.-12:00 noon</td>
<td>Exhibit Show Open</td>
</tr>
<tr>
<td>10:45-11:30 a.m.</td>
<td>Goodman Lecture</td>
</tr>
<tr>
<td>10:45 a.m.-12:00 noon</td>
<td>Controversy Session</td>
</tr>
<tr>
<td>12:00 noon-4:00 p.m.</td>
<td>Poster Discussion Sessions</td>
</tr>
<tr>
<td>12:15-3:45 p.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>12:30-3:00 p.m.</td>
<td>Sympoisa</td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

PUBLICATION OF THE CALL FOR ABSTRACTS

This Call for Abstracts appears in a booklet that was mailed in September 1998 to all AACR members and to nonmembers who have expressed an interest in AACR meetings in the past. It is also published in the September 15, October 1, and October 15 issues of Clinical Cancer Research and in the October issues of Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention. Additional copies are available from the Meetings Department in the AACR Office at 215-440-9300 (Telephone), 215-440-9313 (FAX), and meetings@aacr.org (E-mail).

HOW TO REGISTER

The advance registration form appears on Page 32, and important details about the registration process appear on Page 31. Please note the following important deadlines:

December 1, 1998: New, Reduced Rate "Early Bird" Registration
February 1, 1999: Advance Registration to Ensure Receipt of Meeting Publications in March
February 22, 1999: All Registration by Mail
March 26, 1999: Cancellation of Advance Registration to Receive Refund (less administrative fee)

On-Site registration will be possible at the Pennsylvania Convention Center from April 10-14, 1999.

SCIENTIFIC PROGRAM

Details of the 1999 Program that are currently available appear on the inside front cover of this booklet. A tentative schedule of events appears on Page 3. Regular updates will be posted on the Association's Website (http://www.aacr.org).

ANNUAL MEETING PUBLICATIONS

The Annual Meeting Program contains the authors, titles, times, and locations of all presentations at the annual meeting. The Proceedings of the American Association for Cancer Research contains the abstracts of all peer-reviewed papers accepted for presentation at the annual meeting. All active, corresponding, and associate members of the AACR who have paid their dues for 1999 receive the Program and Proceedings as part of their dues payments. Nonmember and predoctoral student registrants receive the Program, and nonmember registrants also receive the Proceedings as part of their registration fees. Additional copies of the Proceedings may be purchased at a cost of $35 for members and $45 for nonmembers. The Association will mail only badges and receipts to overseas advance registrants who do not pay the postage surcharge described on the advance registration form. If you register in advance and do not receive your publication(s) before you depart for the meeting, please bring your receipt with you to the Issue Pickup Booth in the Registration Area at the Pennsylvania Convention Center. Show your receipt at the Booth to receive the appropriate publication(s).

ELECTRONIC PUBLICATION OF AACR PROGRAM AND PROCEEDINGS

An electronic version of the AACR Program and Proceedings will be available at the AACR's Website in March 1999. It will be possible to search the full text of abstracts of papers being presented for key words and to develop a personal schedule of sessions of interest.

SUPPORT FOR ATTENDANCE

See Page 7 of this booklet for details about the following awards for qualified participants in the annual meeting:

- Travel Awards for Young Investigators Who Are Authors of Outstanding Abstracts: These awards are given to graduate and medical students, postdoctoral fellows, and physicians in training who, in the opinion of the Program Committee, have submitted outstanding abstracts. No separate application form is necessary. Qualified persons who check box 5A on the abstract form and submit the abstract by the November 6, 1998, deadline are automatically considered.
- AACR Minority Scholar Awards: Using funds from the Comprehensive Minority Biomedical Program of the NCI, the AACR supports the annual meeting participation of graduate and medical students, postdoctoral fellows, and physicians in training who are members of the following minority groups defined by the NCI as underrepresented in cancer research: African American, Hispanic American, Native American, Alaskan Native, and Native Pacific Islander. Interested candidates should request an application form from the AACR Minority Scholar Award Coordinator at 215-440-9300 (Telephone), 215-440-9412 (FAX), and felder@aacr.org (E-mail). This form must be completed and returned by December 4, 1998.
- AACR-HBCU Faculty Award In Cancer Research. The AACR has received a grant from the Comprehensive Minority Biomedical Program of the NCI to support participation in the annual meeting by faculty members at Historically Black Colleges and Universities (HBCU's). Applicants must have full-time appointments at the level of Assistant Professor or above and be engaged in meritorious basic, clinical, or translational cancer research at an HBCU. Information and application forms are available from the AACR's HBCU Award Coordinator at 215-440-9300 (Telephone), 215-440-9412 (FAX), and felder@aacr.org (E-mail). The deadline for receipt of applications in the AACR Office will be December 4, 1998.

HOTEL RESERVATIONS

Please read the instructions for making hotel reservations on Page 23 of this booklet and then make your reservation by telephone, FAX, or Internet. From Saturday, April 10, through Wednesday, April 14, shuttle busing will be provided between the Pennsylvania Convention Center and hotels assigned to AACR registrants according to schedules to be posted in the Center and in the hotels. There will be no shuttle bus service to the Philadelphia Marriott Hotel, the Association's Headquarters Hotel, because it is connected to the Convention Center.

CHILD CARE

The AACR will once again provide professional child care services for infants and children ages 6 months to 11 years of age during the annual meeting. Exact hours and costs of this service will be published in January 1999.

COMMERCIAL EXHIBITS

The 1999 AACR Exhibit Show will be the largest in the Association's history. It will gather together an anticipated 300 companies with the latest products and services for laboratory and clinical research. Exhibit booths will be located in Exhibit Hall B adjacent to the poster sessions. Show hours are as follows:

- Sunday, April 11: 12:00 noon to 5:00 p.m.
- Monday, April 12: 10:00 a.m. to 4:00 p.m.
- Tuesday, April 13: 10:00 a.m. to 4:00 p.m.
- Wednesday, April 14: 9:00 a.m. to 12:00 noon

Complimentary coffee, tea, and soft drinks will be served in the Exhibit Area at specified times on each day that exhibits are open. See the final Program for details.

Please visit the exhibits during the meeting as the firms involved are making a significant contribution to the educational value of the meeting and to the Association's financial stability. If your firm needs an application form for exhibit space, please contact

Ms. Susan Capper AACR Exhibit Manager • Slack Incorporated 6900 Grove Road • Thorofare, NJ 08086 609-848-1000

EMPLOYMENT REGISTER

The AACR will operate an Employment Register in the Convention Center during the 1999 Annual Meeting and will schedule interviews for registered employers and candidates. Instructions and forms for participation in the employment register are available from the AACR Office. Registration will also be possible at the meeting. Candidate and position listings received in the AACR Office by December 7, 1998, will be published in the Proceedings.

SPACE FOR SPECIAL FUNCTIONS

The AACR will entertain requests for space for special functions or receptions in the Philadelphia Marriott, the AACR’s headquarters hotel. Such requests will be handled on a first-come, first-served basis and should be directed to the Meetings Department in the Association Office.

ASSISTANCE FOR HANDICAPPED REGISTRANTS

The AACR is committed to making its meeting accessible to all investigators. Registrants with special requirements for transportation, hotel accommodations, or other facilities connected with the meeting should inform the Association Office of their needs in advance of the meeting by checking the appropriate box on the advance registration form or by contacting the Meetings Department in the Association Office as described in the first paragraph above.
Authors who submit an abstract of a paper for consideration for presentation at the Annual Meeting of the American Association for Cancer Research (AACR) confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting. AACR policy states that the content of submitted abstracts is kept strictly confidential by the members of the Program Committee during the review and pre-publication process. After review of the abstract by the Program Committee, the PRESENTER will be notified about whether it has been accepted for presentation. The PRESENTER of the abstract must be one of the authors of the abstract, and it is expected that he or she will be the first author. Only those abstracts that are deemed acceptable for presentation by the Program Committee will be published in the Proceedings of the American Association for Cancer Research, which will be published in March 1999.

The paper presented at the annual meeting must coincide directly with the scientific content of the abstract submitted and determined to be acceptable by the Program Committee. If for any reason this is not possible, the paper must be withdrawn from presentation. Any requests for withdrawal of an abstract must be made in writing by the SPONSOR or PRESENTER. NOTE: Authors will be assessed a charge for any extraordinary costs incurred as a result of the withdrawal of abstracts after the Proceedings issue is in production.

To provide a well-organized, effective scientific program, the Program Committee will have full discretion to assign papers to minisymposia, poster discussion sessions, and poster sessions.

Minisymposia. Minisymposia will be planned from submitted abstracts. This format serves as a vehicle for the presentation and extensive discussion of developments in timely areas of cancer research.

Authors whose papers are assigned to minisymposia will be informed about the amount of time available for the delivery of their papers. At appropriate intervals, there will be opportunities for the discussion of each paper presented during the session. In addition, these sessions may include an invited talk to bring the subject into current perspective; there will be an introduction and a concluding discussion of the topic.

Poster Discussion Sessions. Poster discussion sessions will be scheduled from submitted abstracts and will run for four hours. The presentation of posters is supplemented by a focused discussion of the research areas under consideration. After presentation of the posters, there will be a one-hour discussion period led by two chairs persons with expertise in the area. Participants will have an opportunity to view the posters again after the discussion.

Prior to the annual meeting, the two chairs persons of these sessions will communicate directly with the authors presenting in the session to obtain more information on the work to be discussed. Authors will be expected to submit the content of their posters to the two chairs persons in advance of the meeting to make the ensuing discussion more effective.

Poster Sessions. Regular poster sessions will extend for four hours. Authors will be required to be present at their posters for the first three hours of the session. Detailed instructions for the preparation of posters will be sent to all authors whose abstracts are accepted for these sessions.

Late-Breaking Research Session. The firm deadline for submission of abstracts for publication in the Proceedings of the American Association for Cancer Research and for presentation at one of the regular sessions at the annual meeting is November 6, 1998. In addition, the AACR will provide an opportunity for the presentation of a few definitive reports of timely and highly significant research findings that become available after the November 6 abstract deadline. The work to be presented in this session must be of major novelty and importance, e.g., the characterization of a new gene in familial cancer or the discovery of a new diagnostic marker. Complete instructions for submission of these abstracts will appear in a forthcoming AACR Annual Meeting announcement and in AACR journals in January 1999. The deadline for submission of abstracts for consideration for the Late-Breaking Research Session will be March 12, 1999.

Scheduling of Presentations. The AACR will do its utmost to assist any author who, for religious reasons, cannot present a paper on a particular day of the week. However, the complexities of scheduling thousands of papers for this multidisciplinary cancer research meeting require that sufficient notice from authors be given to the Program Committee. Authors who need special assistance with regard to the scheduling of their papers must enclose written requests along with their submitted abstracts.

SPONSORSHIP REGULATIONS

1. The SPONSOR must be a member of the Association in good standing. That is, an active, corresponding, or associate member must have paid his or her membership dues through 1998 by the time of the submission of the abstract in order to serve as the SPONSOR of one abstract for the upcoming annual meeting. As stated in the AACR By-Laws, honorary and emeritus members are exempt from the payment of dues; thus this regulation does not apply to them.

2. Each member of the AACR may SPONSOR only one abstract. There are no exceptions to this regulation. This privilege may be used in one of two ways: (a) the SPONSOR may be one of the authors of the abstract, or (b) the SPONSOR may sign the abstract form on behalf of the authors who may be either members or nonmembers of the AACR.

3. Each submitted abstract must carry the SPONSOR'S AACR Membership Number. This number appears on the AACR Membership Card and below the member's name in the 1997-1998 AACR Directory of Members. The SPONSOR must sign the abstract form.
4. A member or nonmember may be listed as a coauthor on more than one abstract, provided that each abstract has a different member SPONSOR.

5. The SPONSOR is obligated to ascertain that all authors are aware of the content of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

Special Limitations on Submissions by Associate Members.

An associate member in good standing may SPONSOR his or her own abstract provided that (a) he or she is the PRESENTER of the abstract, and (b) an active or corresponding member in good standing also signs the abstract form ENDORSING the work. The ENDORSER does not thereby lose his or her own sponsorship privilege. NOTE: An associate member may SPONSOR only one abstract, and he or she must also be the PRESENTER of that abstract.

COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE SPONSOR. Adherence to these rules will be verified. Violations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee.

INSTRUCTIONS FOR THE PREPARATION AND SUBMISSION OF ABSTRACTS

Each submitted abstract must carry the name, AACR Member Number, and signature of the SPONSOR on the appropriate lines of the abstract form. Each AACR member may SPONSOR only one abstract.

CONTENT OF ABSTRACTS

Authors who submit an abstract of a paper confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting.

Members of the Program Committee will evaluate the scientific quality of the submitted abstract on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Authors should be particularly cognizant of the importance of setting forth the objectives and hypotheses of the study in a clear, succinct manner and of summarizing the new, unpublished results. If the abstract is poorly written such that the Program Committee cannot determine its novelty and importance, the paper will not be accepted for presentation at the annual meeting.

1. Abstracts must describe in a succinct manner the purposes and results of the research so that the quality, originality, and comprehensiveness of the work can be evaluated by the Program Committee. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature.

2. Titles should be indicative of the content of the abstract. All words necessary to identify the subject matter should be included in the title to facilitate electronic retrieval (CD-ROM or online searches). Avoid nonstandard abbreviations in abstract titles.

3. Abbreviations may be used in the body of an abstract if they are defined at their first mention in the text. Complex therapeutic regimens must be identified.

4. NOTE: The AACR is committed to the advancement of cancer research and the cure and prevention of cancer through the facilitation of communication and full dissemination of knowledge among scientists and others dedicated to the cancer problem. Therefore, the AACR requires strict compliance with the following regulation:

When biological or chemical data pertaining to chemical entities are an integral part of the research, the chemical structure, method of preparation, and patent or reference numbers must be presented. If for any reason this information cannot be given when the paper is presented at the annual meeting, the abstract on this work should not be submitted for consideration.

5. Because of administrative and time constraints, supplemental data submitted along with the abstract cannot be transmitted to the Program Committee for review.

GENERAL INSTRUCTIONS FOR THE SUBMISSION OF ABSTRACTS

The AACR will not accept abstracts for the 1999 Annual Meeting via Internet submission or by fax or e-mail delivery. Abstracts must be submitted on the official 1999 AACR abstract form. Two abstract forms are enclosed. Please pass one on to a colleague if you do not need it for your own use. The blank form may also be photocopied for use by others. Additional abstract forms may be obtained by calling or writing to the AACR Office. The blank form is also available as a PDF document that can be downloaded and printed from the AACR Website: <http://www.aacr.org/meeting.htm>. Instructions for completing the abstract form are given on the following pages.

The accuracy of the submitted abstract is the responsibility of the authors. Every effort will be made to publish the abstract exactly as submitted on the abstract form. Although abstracts will be typeset for print and electronic distribution, they will not be edited or corrected by AACR Staff. Therefore, authors should prepare and proofread their abstracts carefully prior to submission. Errors made on your submitted abstract are likely to appear in print.

Please do not submit applications for active or corresponding membership along with your abstracts. These should be sent directly to the Membership Services Department in the AACR Office.

ABSTRACT SUBMISSION FEE

A fee of US$40 will be assessed for each abstract submitted for consideration by the Program Committee. This fee offsets some of the costs of processing the abstract. Each abstract must be accompanied by a check for US$40 payable to the American Association for Cancer Research, Inc. - OR - authorization must be provided to charge this fee to a credit card that is accepted by AACR (see Item 8 on the abstract form). All checks must be drawn on a United States bank. Please list the PRESENTER’s name on the check. NOTE: Purchase orders will not be accepted.

In cases of the voluntary withdrawal of an abstract by the author, the return of the abstract because of violation of abstract regulations, or the rejection of the abstract for presentation, this submission fee cannot be refunded.
A Temporary Abstract Number will be assigned to your abstract when it arrives at the AACR Office. This number will be listed on the card that is returned to you acknowledging receipt of your abstract. Please reference the Temporary Abstract Number in all subsequent communications with the AACR Office.

ABSTRACT FORM

The official abstract form must be filled out completely and signed in accordance with the instructions. Three (3) photocopies of the completed form must also be submitted. In addition to typing the abstract within the box according to the instructions given below, please provide the information and signatures requested on the abstract form and accompanying materials as follows. (NOTE: The numbered headings below correspond to the numbers on the abstract form.)

1. Category and Subclassification. Choose ONLY ONE category and subclassification. Indicate the category and subclassification in which your paper belongs by typing the appropriate five-character code in the blocks provided. A list of codes for the categories and sub classifications appears on Pages 10-12 of this booklet. The list is also available at the AACR Website. These designations will serve as a guide to the Program Committee in the grouping of abstracts but will not necessarily be the actual titles of scientific sessions to be held at the annual meeting.

2. Sponsor of the Abstract. Type the AACR member number, name, address, telephone and FAX numbers, and e-mail address of the member using his or her membership privilege to SPONSOR the abstract. (Member numbers can be found on an individual's membership card and in the 1997-1998 AACR Directory of Members.) The SPONSOR, who must be a member of the AACR in good standing through 1998, may SPONSOR only one abstract. (See Page 5 for Sponsorship Regulations.)

3. Sponsor Signature. The SPONSOR must sign the form in the space provided to indicate support for the data and interpretations contained in the abstract.

4. Associate Members Only. If an associate member is the SPONSOR AND PRESENTER of the abstract, he or she must ask an active or corresponding member in good standing or an emeritus or honorary member to sign Line 4 of the form as the ENDORSER of the work. Type the name and member number of the ENDORSING member on the appropriate lines.

5. Eligibility for Young Investigator Awards for American and International Scientists.

A. The AACR is very grateful to the growing number of sponsors who help several hundred young investigators attend the annual meeting each year. International travel grants for young scientists are on the rise. For example, ITO EN, Ltd. is underwriting a major enhancement of the AACR's program of young investigator travel grants for Asian scientists and will continue its very generous support of this new program through 2002.

Submission of an abstract by the deadline of November 6 is an absolute prerequisite for receipt of any AACR travel award. Qualified scientists from all countries are therefore encouraged to submit abstracts and to indicate their eligibility for these awards by observing the following instructions: Indicate whether the PRESENTER of the abstract is a medical student, graduate student, physician in training, or postdoctoral fellow from an academic or governmental organization. PRESENTERS who meet these requirements and who are first authors on abstracts given high ratings for scientific merit by the Program Committee may be candidates for a young investigator award. If a PRESENTER is eligible based on the above criteria and is under consideration, a letter confirming his or her status, submitted on the official letterhead of the PRESENTER's institution and signed by the registrar, dean, or department head of that institution, will be requested at a later date.

B. Minority Scholar Awards in Cancer Research are available if the PRESENTER meets the above-mentioned criteria and is African American, Hispanic American, Native American, Alaskan Native, or Native Pacific Islander. Through a generous grant provided by the Comprehensive Minority Biomedical Program of the National Cancer Institute, funds are available to encourage participation in the annual meeting by minority groups which have been traditionally underrepresented in cancer and biomedical research. Eligible scientists are young, full-time predoctoral (graduate or medical) students, postdoctoral fellows, and physicians in training who are either engaged in cancer research, or who have training that could lead to contributions in this field. Only citizens of the United States and Canada or scientists who are permanent residents in these countries may receive one of these awards.

Although preference will be shown to authors of abstracts that have been accepted for presentation at the 1999 AACR Annual Meeting, this is not a requirement for the Minority Scholar award. Awardees will be selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit of their attendance at the annual meeting. An advisory committee consisting of senior members of the AACR carefully reviews submitted applications and letters of reference. The award will consist of partial support for the registration, travel, and subsistence expenses incurred in connection with their attendance at the annual meeting.

Persons checking this box will receive an application form which must be completed and returned to the AACR by December 4, 1998. Applicants will be chosen from both minority institutions and the larger body of universities, colleges, and research institutes. If accepted, applicants are expected to attend at least three full days of scientific sessions at the annual meeting and participate in all planned activities for the awardees. They are also required to submit a report commenting on the scientific sessions they attended at the annual meeting and on the Minority Scholar Program.

C. AACR-HBCU Faculty Awards in Cancer Research are available to full-time faculty members of Historically Black Colleges and Universities (HBCU’s). Supported by a generous grant provided by the Comprehensive Minority Biomedical Program of the National Cancer Institute, these awards will be presented to scientists at the level of Assistant Professor or above at an HBCU who are engaged in meritorious basic, clinical, or translational cancer research. Awardees will receive financial support for their participation in the Annual Meeting up to a maximum of $1,500.

The purpose of this Award program is to increase the scientific knowledge base of faculty members at HBCU’s and to encourage them and their students to pursue careers in cancer research. The selection of awardees will be made by a multidisciplinary AACR Award Committee consisting of experts in all aspects of basic, clinical, and translational research. Although preference will be shown to authors of abstracts that have been accepted for presentation at the 1999 AACR Annual Meeting, this is not a requirement for the AACR-HBCU Faculty Awards. Other selection criteria will include the candidate’s publications and current grant support as evidence of a
commitment to and of achievement in cancer research. The Committee will also assess the specific benefits that the candidate will derive from attendance at the meeting with particular attention to the candidate’s own statement in this regard.

Persons checking this box will receive an application form which must be completed and returned to the AACR by December 4, 1998. If accepted, applicants are expected to attend at least three full days of scientific sessions at the annual meeting and to participate in all planned activities for awardees. Reimbursement of meeting expenses is contingent upon submission of a report commenting on the scientific sessions they attended and on the AACR-HBCU Faculty Award Program.

6. Presenter of the Abstract. Type the name, AACR member number (if applicable), address, telephone and FAX numbers, and e-mail address of the PRESENTER of the paper in the space provided. The PRESENTER must be one of the authors of the abstract. It is expected that the first author of an abstract will be its PRESENTER.

7. Presenter Signature. The PRESENTER of the paper must sign the form in the space provided to acknowledge that the Copyright Transfer/Conflict of Interest Disclosure Form has been completed, and to give the AACR permission to arrange for audiotape recording and the subsequent sale of audiotape cassettes of the papers delivered orally at the 1999 AACR Annual Meeting. Your advance permission for taping in the event that your paper is among those to be recorded is appreciated.

8. Payment of US$40 Abstract Submission Fee. Please indicate your method of payment. Remember to list the name of the PRESENTER on your enclosed check. If you want the Abstract Submission Fee (US$40) to be billed to your credit card, please fill in the necessary information and sign in the space provided. Purchase orders cannot be accepted.

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in an additional fee of US$40, which will be billed to the SPONSOR.

FORMAT OF ABSTRACTS

Abstracts will be typeset from the paper copy of the abstract form. The accuracy of the submitted abstract is the responsibility of the authors. Careful preparation and proofreading are essential prior to submission. Every effort will be made to publish the abstract exactly as submitted on the abstract form, except in certain instances where changes are made to comply with AACR style. AACR does not assume responsibility for proofreading or correcting any scientific, grammatical, or typographical errors. Therefore, errors made in your submitted abstract are likely to appear in print.

Only abstracts submitted on the official 1999 abstract form will be considered by the Program Committee. Before typing the abstract on the form, read all instructions and examine the sample abstract thoroughly. Prepare your abstract in accordance with the approved format shown in the sample abstract (Page 14). Please note in particular the following regulations concerning format:

Dimensions: The entire abstract, including text, title, authors, and affiliations, must fit within the box provided on the abstract form. The dimensions of the box are 5 inches (12.5 cm) wide x 4 inches (10 cm) high. Do not reduce the abstract mechanically to fit into the box. Type the abstract single spaced.

Type: Abstracts may be printed using laser or ink-jet printers with type no smaller than 10-point. Abstracts may also be prepared using typewriters or daisy-wheel printers with a sharp black ribbon and a printing element no smaller than 12-pitch (elite). Do not use dot matrix printers. Any symbols that must be drawn by hand should be drawn with black ink.

Title: Use boldface type for the title if possible. The first line of the title should be flush with the left margin of the abstract box. Capitalize only the first letter of the first word; type the rest in lower case except where lower case is incorrect, e.g., “DNA.” Avoid nonstandard abbreviations in the title. (See Cancer Research Instructions for Authors, Vol. 58: 180-186, 1998, for a list of standard abbreviations.) Type a period at the end of the title.

Authors’ Names: Type the authors’ names as a group. For each author, type surname first followed by given name and initials. Omit academic degrees. Do not use footnote numbers or symbols after the authors’ names to refer to their individual affiliations. See next paragraph.

Affiliations: List affiliations as a group at the end of the list of authors’ names. For each affiliation, type the name of the institution, city, state (in abbreviated form), zip code, and country (other than the U.S.). Separate each affiliation with a semicolon. An example appears below:

Moody, T.W., Cassibang, M., Rosenstein, J., Gozes, Y., Ben Av, P., and Hla, T., Division of Clinical Sciences, National Cancer Institute, Rockville, MD 20850; Israel Institute for Biological Research, Ness-Ziona, 74100 Israel; and Holland Laboratory, American Red Cross, Rockville, MD 20855.

We prefer that you do not key the affiliation of each author to his/her name. However, if you are obligated to do so, DO NOT use footnote numbers or symbols after an author’s name to refer to his/her affiliation because they are difficult to distinguish in print. Instead, put the author’s initials in parentheses at the end of his/her affiliation as shown below:

Iwamura, T., Caffrey, T.C., Kawano K., Yamanari, H., Setoguchi, T., and Hollingsworth, M.A., Miyazaki Prefectural General Hospital, Miyazaki 880, Japan (T.I.); The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE 68198 (T.I., T.C.C., M.A.H.); and Miyazaki Medical College, Miyazaki 889-16, Japan (T.I., K.K., H.Y., T.S.).

Text: Begin the text on a separate line after the affiliations. Type the text single spaced in one paragraph. Nonstandard abbreviations are permitted in the text of the abstract if they appear in parentheses immediately after the term being abbreviated at the first usage of that term in the text. Tables, charts, illustrations, halftones, and color photographs are not acceptable as part of your abstract and should not be submitted.

INSTRUCTIONS FOR COMPLETING THE COPYRIGHT TRANSFER/CONFLICT OF INTEREST DISCLOSURE FORM

All PRESENTERS must submit the signed original plus one copy of this completed form along with their abstracts.

Copyright Transfer. The PRESENTER of the paper, as an author of the abstract and on behalf of all authors, must check the appropriate box and sign this section of the form.

Conflict of Interest Disclosure. The AACR has applied for accreditation of the Annual Meeting as an educational activity
for Category 1 credits towards the Physician's Recognition Award Program of the American Medical Association. The Accreditation Council for Continuing Medical Education requires that all PRESENTERS at accredited activities declare whether they have any financial or other interest which might be construed as resulting in an actual, potential, or apparent conflict of interest in the work presented. The AACR Board of Directors has accepted this principle and has made this declaration a prerequisite of abstract submission. The existence of financial interests or other relationships of a commercial nature is not regarded by the AACR as creating a presumption of impropriety. Rather, the AACR desires to make as much relevant information available as possible to those reviewing the data being presented.

All PRESENTERS, whether or not they have a financial or other interest in the work they intend to present, must complete and sign the Conflict of Interest Disclosure section of the form on Page 13 of this booklet. The form must also be downloaded as a PDF file from the AACR's Website. Failure to submit this form along with an abstract form by November 6, 1998, will result in return of the abstract to the PRESENTER without consideration by the Program Committee.

MAILING INSTRUCTIONS

1. Abstracts must be received in the office of the American Association for Cancer Research no later than November 6, 1998. Submission at an earlier date would be appreciated. The AACR urges investigators working outside of the United States to send their abstracts well ahead of the deadline date or to use one of the international courier services that offer delivery within a few days. The deadline for receipt will be applied uniformly to all abstracts regardless of their origin. FAX or other electronic transmittals will not be accepted.

2. Enclose the following materials unfolded and with cardboard backing in an envelope of suitable size:
   A. An original plus three (3) legible copies of the completed abstract form signed by the SPONSOR and PRESENTER.
   B. A check for US$40 payable to the American Association for Cancer Research, Inc. All checks must be drawn on United States banks. PLEASE LIST THE NAME OF THE PRESENTER ON YOUR CHECK. If you wish to charge this amount to your credit card, fill out and sign Item 8 on the abstract form. Purchase orders are not acceptable for payment of the abstract submission fee.
   C. The completed and signed Copyright Transfer/Conflict of Interest Disclosure Form plus one photocopy.
   D. The Acknowledgment Card attached to this announcement. The names of the authors and the title of the paper should be filled in on the card prior to submission. The card will be returned to you showing the Temporary Abstract Number assigned to your abstract. This number should be referenced in all correspondence or telephone calls to the AACR Office. PRESENTER: To ensure receipt of the Acknowledgment Card, put your own address on the reverse of the card and affix proper postage.
   E. One stamped, regular letter-sized envelope (about 4 x 9.5 inches, 10.2 x 24.2 cm) addressed to the PRESENTER. The final decision of the Program Committee concerning acceptability for presentation and publication will be returned in this envelope along with any other necessary instructions.

3. Send the materials listed above together in one envelope to:

   American Association for Cancer Research, Inc.
   1999 ANNUAL MEETING ABSTRACT
   Public Ledger Building, Suite 826
   150 S. Independence Mall West
   Philadelphia, PA 19106-3483

4. Do not enclose membership application forms, membership dues, advance registration forms, housing forms, or any other materials in the envelope with your abstract submission. Please submit these documents separately and follow the particular mailing instructions provided on each one.

   Special mailing charges cannot be paid by the AACR. The AACR staff cannot assume responsibility for abstracts that are not delivered directly to the premises.

SUBMISSION OF CORRECTED ABSTRACTS

If after submitting your abstract you discover an error, please do not submit a corrected abstract until you have received an acknowledgment card containing the Temporary Abstract Number of your original submission. You may then submit a corrected abstract in strict accordance with the following instructions:

1. On a photocopy of the original abstract, indicate the correction(s) you are making.

2. On an official abstract form in the box provided, type the full text of the resubmitted abstract prepared according to the format instructions above. Answer all the questions on the form.

3. Label both the original and resubmitted abstract forms in the upper right-hand corner with your Temporary Abstract Number and the word "Resubmission."

4. Send the corrected original abstract and an original and three copies of the resubmitted abstract on the official form to the address given above. Write or type the word "Resubmission" on the mailing envelope.

   Authors will be charged for any extraordinary costs incurred as a result of abstracts being resubmitted or withdrawn after the Proceedings is in production. The AACR will not be responsible for the acceptance and processing of corrected abstracts that are not submitted in compliance with the above regulations. No substantive changes may be made in abstracts after they have undergone scientific review, and the AACR cannot accept any resubmission or comply with any request for withdrawal of an abstract that will delay the publication of the Proceedings.

THE NOVEMBER 6, 1998 DEADLINE WILL BE STRICTLY ENFORCED.
<table>
<thead>
<tr>
<th>BL</th>
<th>1999 ABSTRACT CATEGORIES AND SUBCLASSIFICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BL1</td>
<td>CELL AND TUMOR BIOLOGY</td>
</tr>
<tr>
<td>BL1-01</td>
<td>Cell Growth Signaling Pathways: Cell Biology Aspects</td>
</tr>
<tr>
<td>BL1-02</td>
<td>Receptors: structure and function</td>
</tr>
<tr>
<td>BL1-03</td>
<td>Signaling: membrane to nucleus</td>
</tr>
<tr>
<td>BL1-04</td>
<td>Autocrine-paracrine signaling</td>
</tr>
<tr>
<td>BL1-05</td>
<td>Physiological-organismic homeostasis</td>
</tr>
<tr>
<td>BL1-06</td>
<td>Cell-matrix interactions</td>
</tr>
<tr>
<td>BL1-07</td>
<td>Adhesion and cytoarchitectural inputs</td>
</tr>
<tr>
<td>BL1-08</td>
<td>Cell-cell interactions: communication/GAP junctions</td>
</tr>
<tr>
<td>BL1-09</td>
<td>Cell-cell adhesion receptors</td>
</tr>
<tr>
<td>BL1-10</td>
<td>Tumor-stromal cell interactions</td>
</tr>
<tr>
<td>BL1-11</td>
<td>Organogenesis and tumor development</td>
</tr>
<tr>
<td>BL1-12</td>
<td>Cell and tissue kinetics/physiology</td>
</tr>
<tr>
<td>BL1-13</td>
<td>Tissue remodeling and regeneration</td>
</tr>
<tr>
<td>BL1-14</td>
<td>Wound healing and tissue repair</td>
</tr>
<tr>
<td>BL1-15</td>
<td>Animal models of tissue host-tumor interactions</td>
</tr>
<tr>
<td>BL1-16</td>
<td>Other</td>
</tr>
<tr>
<td>BL2</td>
<td>CELL DEATH SIGNALING</td>
</tr>
<tr>
<td>BL2-01</td>
<td>Transcriptional control of apoptosis</td>
</tr>
<tr>
<td>BL2-02</td>
<td>Genetic and developmental controls</td>
</tr>
<tr>
<td>BL2-03</td>
<td>Receptor coupled signaling to apoptosis</td>
</tr>
<tr>
<td>BL2-04</td>
<td>Death protein networks</td>
</tr>
<tr>
<td>BL2-05</td>
<td>ICE proteases/caspsases: cascades/substrates</td>
</tr>
<tr>
<td>BL2-06</td>
<td>Caspase inhibitors: experimental and preclinical</td>
</tr>
<tr>
<td>BL2-07</td>
<td>Enzymology of apoptosis</td>
</tr>
<tr>
<td>BL2-08</td>
<td>Nuclear targets/effectors of apoptosis</td>
</tr>
<tr>
<td>BL2-09</td>
<td>Growth factors and other survival signals</td>
</tr>
<tr>
<td>BL2-10</td>
<td>Cell adhesion/cell-cell interactions in apoptosis</td>
</tr>
<tr>
<td>BL3</td>
<td>TUMOR PROGRESSION, INVASION, AND METASTASIS</td>
</tr>
<tr>
<td>BL3-01</td>
<td>Tissue degradation: protease-inhibitor systems</td>
</tr>
<tr>
<td>BL3-02</td>
<td>Motility: receptors and signaling</td>
</tr>
<tr>
<td>BL3-03</td>
<td>Adhesion-extravasation-migration</td>
</tr>
<tr>
<td>BL3-04</td>
<td>Inflammation and tumor development</td>
</tr>
<tr>
<td>BL3-05</td>
<td>Macrophage-tumor interactions</td>
</tr>
<tr>
<td>BL3-06</td>
<td>Organ-specific metastasis</td>
</tr>
<tr>
<td>BL3-07</td>
<td>New metastasis genes</td>
</tr>
<tr>
<td>BL3-08</td>
<td>Mechanisms of cell motility and migration</td>
</tr>
<tr>
<td>BL3-09</td>
<td>Mechanisms of bone metastasis</td>
</tr>
<tr>
<td>BL3-10</td>
<td>Xenograft-metastasis systems and their models</td>
</tr>
<tr>
<td>BL3-11</td>
<td>O xúcct metastasis: detection</td>
</tr>
<tr>
<td>BL3-12</td>
<td>Other</td>
</tr>
<tr>
<td>BL4</td>
<td>HOST-TUMOR INTERACTIONS: ANGIogenesis AND Microcirculation</td>
</tr>
<tr>
<td>BL4-01</td>
<td>Mechanisms and signaling events</td>
</tr>
<tr>
<td>BL4-02</td>
<td>Angiogenic factors and receptors</td>
</tr>
<tr>
<td>BL4-03</td>
<td>Angiogenesis inhibitors: endogenous and synthetic</td>
</tr>
<tr>
<td>BL4-04</td>
<td>Endothelial cell functions</td>
</tr>
<tr>
<td>BL4-05</td>
<td>Blood flow and microcirculation</td>
</tr>
<tr>
<td>BL4-06</td>
<td>Vascular, lymphatic, and interstitial transport</td>
</tr>
<tr>
<td>BL4-07</td>
<td>Physiological resistance to cancer therapy</td>
</tr>
<tr>
<td>BL4-08</td>
<td>Vascular structural reorganization</td>
</tr>
<tr>
<td>BL4-09</td>
<td>Other</td>
</tr>
<tr>
<td>MB</td>
<td>MOLECULAR BIOLOGY</td>
</tr>
<tr>
<td>MB1</td>
<td>CANcer Genetics 1: New Loci and Mechanisms of Genomic Alterations</td>
</tr>
<tr>
<td>MB1-01</td>
<td>New human cancer genes: mapping of loci and cloning</td>
</tr>
<tr>
<td>MB2</td>
<td>CANcer Genetics II: Tumor Suppressor Genes - Structure and Function</td>
</tr>
<tr>
<td>MB2-01</td>
<td>New mutations in human tumors</td>
</tr>
<tr>
<td>MB2-02</td>
<td>Genotype/phenotype correlations</td>
</tr>
<tr>
<td>MB3</td>
<td>CANcer Genetics III: Human and Retroviral Oncogenes - Structure and Function/Viral Oncogenesis</td>
</tr>
<tr>
<td>MB3-01</td>
<td>Oncogenes</td>
</tr>
<tr>
<td>MB3-02</td>
<td>Growth factors and soluble molecules</td>
</tr>
<tr>
<td>MB3-03</td>
<td>Protein tyrosine kinases: receptor and nonreceptor</td>
</tr>
<tr>
<td>MB3-04</td>
<td>Protein serine-threonine kinases: receptor and nonreceptor</td>
</tr>
<tr>
<td>MB3-05</td>
<td>Phosphatases: receptor and nonreceptor</td>
</tr>
<tr>
<td>MB3-06</td>
<td>Cytolesic adipocytokines and intermediate molecules</td>
</tr>
<tr>
<td>MB3-07</td>
<td>Guanetidine binding proteins and effectors</td>
</tr>
<tr>
<td>MB3-08</td>
<td>Mitogenic signaling kinase cascades</td>
</tr>
<tr>
<td>MB3-09</td>
<td>Oncogenic transcription factors</td>
</tr>
<tr>
<td>MB3-10</td>
<td>New oncogenes</td>
</tr>
<tr>
<td>MB3-11</td>
<td>Other</td>
</tr>
<tr>
<td>MB4</td>
<td>Gene Expression and Epigenetic Regulation</td>
</tr>
<tr>
<td>MB4-01</td>
<td>Cancer genome anatomy: comparative expression patterns</td>
</tr>
<tr>
<td>MB4-02</td>
<td>New methods in tumor microdissection/comparative expression</td>
</tr>
<tr>
<td>MB4-03</td>
<td>DNA methylation and maintenance</td>
</tr>
<tr>
<td>MB4-04</td>
<td>Enzymology of DNA methylation/ modification</td>
</tr>
<tr>
<td>MB4-05</td>
<td>Imprinting and allele-specific expression</td>
</tr>
<tr>
<td>MB4-06</td>
<td>Silencing and reactivation of gene expression</td>
</tr>
<tr>
<td>MB4-07</td>
<td>Telomeres and telomerase</td>
</tr>
<tr>
<td>MB4-08</td>
<td>Cellular aging and senescence: molecular studies</td>
</tr>
<tr>
<td>MB4-09</td>
<td>Other</td>
</tr>
<tr>
<td>MB5</td>
<td>Gene Regulation and Transcriptional Control of Cell Cycle</td>
</tr>
<tr>
<td>MB5-01</td>
<td>Basic mechanisms of transcription: biotechnology/chemistry/physiology</td>
</tr>
<tr>
<td>MB5-02</td>
<td>Transcription-coupled repair: genetics/biochemistry</td>
</tr>
<tr>
<td>MB5-03</td>
<td>Promoter enhancer analysis</td>
</tr>
<tr>
<td>MB5-04</td>
<td>Growth factor-inducible gene expression</td>
</tr>
<tr>
<td>MB5-05</td>
<td>Oncogenic transcription factor function: leukemias/lymphomas/solid tumors</td>
</tr>
<tr>
<td>MB5-06</td>
<td>Transgenic models of promoter and transcription factor function</td>
</tr>
<tr>
<td>MB5-07</td>
<td>Protein-protein interaction in transcription factor function</td>
</tr>
<tr>
<td>MB5-08</td>
<td>Protein phosphorylation and control of gene expression</td>
</tr>
<tr>
<td>MB5-09</td>
<td>Transcriptional control of cell differentiation</td>
</tr>
<tr>
<td>MB5-10</td>
<td>Transcriptional programs and organogenesis</td>
</tr>
<tr>
<td>MB5-11</td>
<td>Chromatin structure/higher order regulation</td>
</tr>
<tr>
<td>MB5-12</td>
<td>Gene expression effects and genomic sensing</td>
</tr>
<tr>
<td>MB5-13</td>
<td>Antisense control of gene expression</td>
</tr>
<tr>
<td>MB5-14</td>
<td>Posttranscriptional and translational control</td>
</tr>
<tr>
<td>MB5-15</td>
<td>New methods for multiplex analysis of gene expression</td>
</tr>
<tr>
<td>MB5-16</td>
<td>Structural biology of transcription factors</td>
</tr>
<tr>
<td>MB5-17</td>
<td>Other</td>
</tr>
<tr>
<td>MB6</td>
<td>Cell Cycle</td>
</tr>
<tr>
<td>MB6-01</td>
<td>Growth factor control of cell cycle</td>
</tr>
<tr>
<td>MB6-02</td>
<td>Genetic control of cell cycle progression</td>
</tr>
<tr>
<td>MB6-03</td>
<td>Cell cycle genetic alterations</td>
</tr>
<tr>
<td>MB6-04</td>
<td>Cell cycle checkpoints</td>
</tr>
<tr>
<td>MB6-05</td>
<td>Checkpoints: genetics and biochemistry</td>
</tr>
<tr>
<td>MB6-06</td>
<td>Cyclins and CDKs</td>
</tr>
<tr>
<td>MB6-07</td>
<td>CDK inhibitors</td>
</tr>
<tr>
<td>MB6-08</td>
<td>Phosphorylation and proteolysis in cell cycle control</td>
</tr>
<tr>
<td>MB6-09</td>
<td>Negative regulation of cell cycle</td>
</tr>
<tr>
<td>MB6-10</td>
<td>Viral oncoproteins and cell cycle regulation</td>
</tr>
<tr>
<td>MB6-11</td>
<td>Other</td>
</tr>
<tr>
<td>CG</td>
<td>CARCINOGENESIS</td>
</tr>
<tr>
<td>CG1</td>
<td>Biomarkers, Premalignant Lesions, and Risk Assessment</td>
</tr>
<tr>
<td>CG1-01</td>
<td>Biomarkers of exposure to carcinogens</td>
</tr>
<tr>
<td>CG1-02</td>
<td>Environmental carcinogenesis</td>
</tr>
<tr>
<td>CG1-03</td>
<td>Carcinogenesis in fish models</td>
</tr>
<tr>
<td>CG1-04</td>
<td>Genetic susceptibility and risk assessment</td>
</tr>
<tr>
<td>CG1-05</td>
<td>Predictive assays for carcinogenicity</td>
</tr>
<tr>
<td>CG1-06</td>
<td>Premalignant lesions</td>
</tr>
<tr>
<td>CG1-07</td>
<td>Toxicology and carcinogenesis</td>
</tr>
<tr>
<td>CG1-08</td>
<td>Drug metabolizing enzymes</td>
</tr>
<tr>
<td>CG1-09</td>
<td>GSH/GST</td>
</tr>
<tr>
<td>CG1-10</td>
<td>Other</td>
</tr>
<tr>
<td>CG2</td>
<td>Molecular Carcinogenesis:</td>
</tr>
<tr>
<td></td>
<td>Metabolism, DNA Lesions, Mutagenesis, and DNA Repair</td>
</tr>
<tr>
<td>CG2-01</td>
<td>Biochemical aspects of carcinogen function: enzymatic bioactivation</td>
</tr>
<tr>
<td>CG2-02</td>
<td>Biochemistry of DNA repair</td>
</tr>
<tr>
<td>CG2-03</td>
<td>DNA adducts: identification and conformational effects</td>
</tr>
<tr>
<td>CG2-04</td>
<td>DNA adducts: repair and sequence specificity</td>
</tr>
<tr>
<td>CG2-05</td>
<td>Genetic and cytogenetic alterations</td>
</tr>
<tr>
<td>CG2-06</td>
<td>Metabolism and activation of carcinogens in animal models and humans</td>
</tr>
<tr>
<td>CG2-07</td>
<td>Molecular responses to DNA damage</td>
</tr>
<tr>
<td>CG2-08</td>
<td>Mutagenesis</td>
</tr>
<tr>
<td>CG2-09</td>
<td>Mutational spectrum of carcinogens</td>
</tr>
<tr>
<td>CG2-10</td>
<td>Oxygen radicals</td>
</tr>
<tr>
<td>CG2-11</td>
<td>Other</td>
</tr>
<tr>
<td>CG3</td>
<td>Promotion and Progression</td>
</tr>
<tr>
<td>CG3-01</td>
<td>Cellular transformation</td>
</tr>
<tr>
<td>CG3-02</td>
<td>Growth factors in progression</td>
</tr>
<tr>
<td>CG3-03</td>
<td>Mesenchymal/epithelial interactions</td>
</tr>
<tr>
<td>CG3-04</td>
<td>Signal transduction</td>
</tr>
<tr>
<td>CG3-05</td>
<td>Tumor promotion and progression</td>
</tr>
<tr>
<td>CG3-06</td>
<td>Other</td>
</tr>
<tr>
<td>EP</td>
<td>EPIDEMIOLOGY</td>
</tr>
<tr>
<td>EP1</td>
<td>Analytical Epidemiology in Populations</td>
</tr>
<tr>
<td>EP1-01</td>
<td>Behavioral epidemiology</td>
</tr>
<tr>
<td>EP1-02</td>
<td>Cancer in minority and medically underserved populations</td>
</tr>
<tr>
<td>EP1-03</td>
<td>Diet, nutrition, and lifestyle factors</td>
</tr>
<tr>
<td>EP1-04</td>
<td>Environmental and occupational etiology</td>
</tr>
<tr>
<td>EP1-05</td>
<td>Radiation exposure and cancer risk</td>
</tr>
<tr>
<td>EP1-06</td>
<td>Gene-environment interactions</td>
</tr>
<tr>
<td>EP1-07</td>
<td>Human tumor viruses and other infectious agents in susceptible populations</td>
</tr>
<tr>
<td>EP1-08</td>
<td>Genetic polymorphisms and metabolizing enzymes</td>
</tr>
<tr>
<td>EP1-09</td>
<td>Preneoplastic lesions</td>
</tr>
<tr>
<td>EP1-10</td>
<td>Methodology, computer modeling, and bioinformatics</td>
</tr>
<tr>
<td>EP1-11</td>
<td>Other</td>
</tr>
<tr>
<td>EP2</td>
<td>Molecular and Genetic Epidemiology</td>
</tr>
<tr>
<td>EP2-01</td>
<td>Genetic markers and biomarkers in epidemiology</td>
</tr>
<tr>
<td>EP2-02</td>
<td>Familial cancer genetics</td>
</tr>
<tr>
<td>EP2-03</td>
<td>Cancer syndromes</td>
</tr>
<tr>
<td>EP2-04</td>
<td>Genotype/phenotype correlations in cancer families</td>
</tr>
<tr>
<td>EP2-05</td>
<td>Susceptibility and risk assessment</td>
</tr>
<tr>
<td>EP2-06</td>
<td>Genetic counseling and ethical issues</td>
</tr>
<tr>
<td>EP2-07</td>
<td>Cancer surveillance in high-risk populations</td>
</tr>
<tr>
<td>EP2-08</td>
<td>Proactive cancer screening</td>
</tr>
<tr>
<td>EP2-09</td>
<td>Other</td>
</tr>
<tr>
<td>PR</td>
<td>PREVENTION/BASIC SCIENCE AND CLINICAL STUDIES</td>
</tr>
<tr>
<td>PR1</td>
<td>Preclinical Prevention Studies:</td>
</tr>
<tr>
<td></td>
<td>Markers and Mechanisms</td>
</tr>
<tr>
<td>PR1-01</td>
<td>Animal/transgenic models in promotion and prevention</td>
</tr>
<tr>
<td>PR1-02</td>
<td>Biological and biochemical mechanisms in prevention</td>
</tr>
<tr>
<td>PR1-03</td>
<td>Biomarkers and intervention studies</td>
</tr>
<tr>
<td>PR1-04</td>
<td>Molecular markers in prevention research</td>
</tr>
<tr>
<td>PR1-05</td>
<td>Caloric restriction</td>
</tr>
<tr>
<td>PR1-06</td>
<td>Cellular models in prevention research</td>
</tr>
<tr>
<td>PR1-07</td>
<td>Chemoprevention</td>
</tr>
<tr>
<td>PR1-08</td>
<td>Diet, nutrition, and cancer</td>
</tr>
<tr>
<td>PR1-09</td>
<td>Genetic influences on diet and cancer</td>
</tr>
<tr>
<td>PR1-10</td>
<td>Genetic susceptibility and prevention</td>
</tr>
<tr>
<td>PR1-11</td>
<td>Hormones and chemoprevention</td>
</tr>
<tr>
<td>PR1-12</td>
<td>Modulators of arachidonic acid metabolism</td>
</tr>
<tr>
<td>PR1-13</td>
<td>Other</td>
</tr>
<tr>
<td>PR2</td>
<td>Clinical Prevention Studies</td>
</tr>
<tr>
<td>PR2-01</td>
<td>Biomarkers and intervention studies</td>
</tr>
<tr>
<td>PR2-02</td>
<td>Chemoprevention trials</td>
</tr>
<tr>
<td>PR2-03</td>
<td>Studies at the interface of cancer prevention and chemotheraphy</td>
</tr>
<tr>
<td>PR2-04</td>
<td>Physiological and lifestyle effects on chemoprevention</td>
</tr>
<tr>
<td>PR2-05</td>
<td>Prevention clinical trials</td>
</tr>
<tr>
<td>PR2-06</td>
<td>Prevention of second cancers</td>
</tr>
<tr>
<td>PR2-07</td>
<td>Prevention studies in high-risk populations</td>
</tr>
<tr>
<td>PR2-08</td>
<td>Other</td>
</tr>
<tr>
<td>CL</td>
<td>CLINICAL RESEARCH</td>
</tr>
<tr>
<td>CL1</td>
<td>Phase I-III Clinical Trials</td>
</tr>
<tr>
<td>CL1-01</td>
<td>AIDS-related malignancies</td>
</tr>
<tr>
<td>CL1-02</td>
<td>Brain/central nervous system cancers</td>
</tr>
<tr>
<td>CL1-03</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>CL1-04</td>
<td>Colon and other gastrointestinal cancers</td>
</tr>
<tr>
<td>CL1-05</td>
<td>Head and neck cancers</td>
</tr>
<tr>
<td>CL1-06</td>
<td>Leukemias and lymphomas</td>
</tr>
<tr>
<td>CL1-07</td>
<td>Lung cancer</td>
</tr>
<tr>
<td>CL1-08</td>
<td>Melanoma and skin cancer</td>
</tr>
<tr>
<td>CL1-09</td>
<td>Ovarian and other gynecological cancers</td>
</tr>
<tr>
<td>CL1-10</td>
<td>Pediatric malignancies</td>
</tr>
<tr>
<td>CL1-11</td>
<td>Prostate and other genitourinary tract cancers</td>
</tr>
<tr>
<td>CL1-12</td>
<td>Sarcomas</td>
</tr>
<tr>
<td>CL1-13</td>
<td>Second cancers</td>
</tr>
<tr>
<td>CL1-14</td>
<td>Other</td>
</tr>
<tr>
<td>CL2</td>
<td>Organ-Site Specific Studies I: Preclinical Research – Tumor Biology and Translational Research</td>
</tr>
<tr>
<td>CL2-01</td>
<td>AIDS-related malignancies</td>
</tr>
<tr>
<td>CL2-02</td>
<td>Brain/central nervous system cancers</td>
</tr>
<tr>
<td>CL2-03</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>CL2-04</td>
<td>Colon and other gastrointestinal cancers</td>
</tr>
<tr>
<td>CL2-05</td>
<td>Head and neck cancers</td>
</tr>
<tr>
<td>CL2-06</td>
<td>Leukemias and lymphomas</td>
</tr>
<tr>
<td>CL2-07</td>
<td>Lung cancer</td>
</tr>
<tr>
<td>CL2-08</td>
<td>Melanoma and skin cancer</td>
</tr>
<tr>
<td>CL2-09</td>
<td>Ovarian and other gynecological cancers</td>
</tr>
<tr>
<td>CL2-10</td>
<td>Pediatric malignancies</td>
</tr>
<tr>
<td>CL2-11</td>
<td>Prostate and other genitourinary tract cancers</td>
</tr>
<tr>
<td>CL2-12</td>
<td>Sarcomas</td>
</tr>
<tr>
<td>CL2-13</td>
<td>Second cancers</td>
</tr>
<tr>
<td>CL2-14</td>
<td>Animal/transgenic models of molecular progression</td>
</tr>
<tr>
<td>CL2-15</td>
<td>Other</td>
</tr>
<tr>
<td>CL3</td>
<td>Organ-Site Specific Studies II: Preclinical Research – Experimental Therapeutics</td>
</tr>
<tr>
<td>CL3-01</td>
<td>AIDS-related malignancies</td>
</tr>
<tr>
<td>CL3-02</td>
<td>Brain/central nervous system cancers</td>
</tr>
<tr>
<td>CL3-03</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>CL3-04</td>
<td>Colon and other gastrointestinal cancers</td>
</tr>
<tr>
<td>CL3-05</td>
<td>Head and neck cancers</td>
</tr>
<tr>
<td>CL3-06</td>
<td>Leukemias and lymphomas</td>
</tr>
<tr>
<td>CL3-07</td>
<td>Lung cancer</td>
</tr>
<tr>
<td>CL3-08</td>
<td>Melanoma and skin cancer</td>
</tr>
<tr>
<td>CL3-09</td>
<td>Ovarian and other gynecological cancers</td>
</tr>
<tr>
<td>CL3-10</td>
<td>Pediatric malignancies</td>
</tr>
<tr>
<td>CL3-11</td>
<td>Prostate and other genitourinary tract cancers</td>
</tr>
<tr>
<td>CL3-12</td>
<td>Sarcomas</td>
</tr>
<tr>
<td>CL3-13</td>
<td>Second cancers</td>
</tr>
<tr>
<td>CL3-14</td>
<td>Animal/transgenic models of molecular progression</td>
</tr>
<tr>
<td>CL3-15</td>
<td>Other</td>
</tr>
<tr>
<td>CL4</td>
<td>Clinical Pharmacology/Modality-based Clinical Research</td>
</tr>
<tr>
<td>CL4-01</td>
<td>Clinical pharmacology</td>
</tr>
<tr>
<td>CL4-02</td>
<td>Clinical toxicology</td>
</tr>
<tr>
<td>CL4-03</td>
<td>Biodistribution/availability</td>
</tr>
<tr>
<td>CL4-04</td>
<td>Pharmaceutics and monitoring</td>
</tr>
<tr>
<td>CL4-05</td>
<td>Prodrugs and activation strategies</td>
</tr>
<tr>
<td>CL4-06</td>
<td>Other</td>
</tr>
<tr>
<td>CL4-07</td>
<td>Modality-based clinical research</td>
</tr>
<tr>
<td>CL4-08</td>
<td>Cell-based therapeutics</td>
</tr>
<tr>
<td>CL4-09</td>
<td>Differentiation therapy</td>
</tr>
<tr>
<td>CL4-10</td>
<td>Gene therapy clinical trials</td>
</tr>
<tr>
<td>CL4-11</td>
<td>Hematopoietic colony stimulating factors</td>
</tr>
<tr>
<td>CL4-12</td>
<td>Multimodality therapy</td>
</tr>
<tr>
<td>CL4-13</td>
<td>Adjuvant chemotherapy</td>
</tr>
<tr>
<td>CL4-14</td>
<td>Clinical reversal of multidrug resistance</td>
</tr>
<tr>
<td>CL4-15</td>
<td>Transplantation: bone marrow and other stem cell approaches</td>
</tr>
<tr>
<td>CL4-16</td>
<td>Alternative medicine research</td>
</tr>
<tr>
<td>CL4-17</td>
<td>Other</td>
</tr>
<tr>
<td>CL5</td>
<td>Molecular Biology/Molecular Oncology in the Clinic</td>
</tr>
<tr>
<td>CL5-01</td>
<td>Advances in genome scanning relevant to the clinic</td>
</tr>
<tr>
<td>CL5-02</td>
<td>Comparative genomic hybridization from the bench to the clinic</td>
</tr>
<tr>
<td>CL5-03</td>
<td>Cytogenetics and clinical molecular genetics</td>
</tr>
<tr>
<td>CL5-04</td>
<td>Minimal residual disease</td>
</tr>
<tr>
<td>CL5-05</td>
<td>Molecular markers of metastasis and progression</td>
</tr>
<tr>
<td>CL5-06</td>
<td>Oncogene-based molecular diagnosis and prognosis</td>
</tr>
<tr>
<td>CL5-07</td>
<td>Tumor staging: correlation of clinical and molecular markers</td>
</tr>
<tr>
<td>CL5-08</td>
<td>Other</td>
</tr>
<tr>
<td>CL6</td>
<td>Supportive Care, Psychosocial Aspects of Cancer, and Survivorship</td>
</tr>
<tr>
<td>CL6-01</td>
<td>Cancer information access and dissemination</td>
</tr>
<tr>
<td>CL6-02</td>
<td>Pain research</td>
</tr>
<tr>
<td>CL6-03</td>
<td>Palliative care</td>
</tr>
<tr>
<td>CL6-04</td>
<td>Psychosocial aspects of cancer</td>
</tr>
<tr>
<td>CL6-05</td>
<td>Survivorship research</td>
</tr>
<tr>
<td>CL6-06</td>
<td>Other</td>
</tr>
</tbody>
</table>

EN | ENDOCRINOLOGY/PRE-Clinical and Clinical |
| EN1 | Molecular and Prediagonal Endocrinology: Receptors and Signal Transduction |
| EN1-01 | Cytokines and receptors |
| EN1-02 | Growth factors and cell surface receptors |
| EN1-03 | Developmental control of hormone receptors |
| EN1-04 | Hormonal control of cell growth and death |
| EN1-05 | Hormone action and inhibitors |
| EN1-06 | Hormones and differentiation |
| EN1-07 | Hormone receptor networks: signal transduction |
| EN1-08 | Nuclear receptors: structure and function |
| EN1-09 | New ligands |
EN1-10 Preclinical studies of endocrine-related cancers
EN1-11 Protein-protein and co-factor interactions
EN1-12 Receptor cross-talk and signaling
EN1-13 Retinoids and receptors
EN1-14 Steroid hormones and receptors
EN1-15 Thyroid hormones and receptors
EN1-16 Other

EN2 Clinical Endocrinology
EN2-01 Hormonal carcinogenesis
EN2-02 Retinoid-based cancer therapy
EN2-03 Hormone receptors and diagnosis/ prognosis
EN2-04 Hormone synthesis, metabolism, and inhibitors
EN2-05 Neuroendocrine and other endocrine factors

EN2-06 Breast
EN2-07 Ectopic hormone production
EN2-08 Gynecological cancers
EN2-09 Prostate and other genitourinary tract cancers
EN2-10 Other
EN2-11 Other

IM IMMUNOLOGY/PRECLINICAL AND CLINICAL
IM1 Tumor Immunobiology: Experimental and Preclinical
IM1-01 Animal/transgenic models for tumor immunology
IM1-02 Antigenic modulation
IM1-03 DNA-based vaccines
IM1-04 Oncogene-directed immunotherapy/vaccines
IM1-05 Tumor suppressor-directed immunotherapy/vaccines
IM1-06 Viral immunology and vaccines
IM1-07 Immunodeficiency/immunosuppression (including AIDS and AIDS-related malignancies)
IM1-08 Immunomodulation
IM1-09 Integrins and cell adhesion molecules
IM1-10 Lymphokines, cytokines, and growth factors
IM1-11 Non-specific effector mechanisms
IM1-12 Specific immunomembranes
IM1-13 Tumor antigens
IM1-14 Other

IM2 Clinical Immunology: Biological Therapy
IM2-01 Antibodies/immunoconjugates
IM2-02 Cancer vaccines
IM2-03 Cellular immunotherapy
IM2-04 Lymphokines and growth factors
IM2-05 Immunodiagnosis
IM2-06 Immunotherapy of human cancer
IM2-07 Transplantation: control of rejection
IM2-08 Other

PT PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(See also CLINICAL RESEARCH, Organ-Site Specific Studies: Preclinical Research-Tumor Biology and Translational Research; Preclinical Research-Experimental Therapeutics; and Clinical Pharmacology/Modality-based Clinical Research)

PT1 Drug Discovery: Design, Screening, and Delivery
PT1-01 Human xenograft models for drug discovery
PT1-02 Biochemical modulators of the therapeutic index
PT1-03 Combination chemotherapy
PT1-04 Differentiation therapy
PT1-05 Drug design: rational/empirical
PT1-06 Combinatorial chemistry-based drug design
PT1-07 Drug screening
PT1-08 New targets
PT1-09 Novel drug delivery systems
PT1-10 Other

PT2 Mechanisms of Drug Action
PT2-01 Cell cycle mechanisms for anticancer drug action
PT2-02 Cellular responses to anticancer drugs
PT2-03 Drug-mediated stimulation of cell death pathways
PT2-04 Intracellular targets
PT2-05 Modulation of DNA repair
PT2-06 Oncogenic transcription factors as targets
PT2-07 Secondary targets
PT2-08 Other

PT3 Drug Resistance I: Multidrug Resistance
PT3-01 Biochemistry of membrane metabolism and transport
PT3-02 Drug transport and metabolism
PT3-03 Non-P-glycoprotein multidrug resistance
PT3-04 P-glycoprotein structure and function
PT3-05 Reversal of multidrug resistance (preclinical)
PT3-06 Other

PT4 Drug Resistance II
PT4-01 Drug transport and metabolism
PT4-02 Glutathione metabolism
PT4-03 Natural products, synthetic drugs, and nucleotide analogs
PT4-04 Novel mechanisms
PT4-05 Regulation of gene expression in drug resistance
PT4-06 Reversal of drug resistance
PT4-07 Other

PT5 Pharmacology and Preclinical Toxicology
PT5-01 Cellular pharmacology
PT5-02 Pharmacogenetics
PT5-03 Pharmacokinetics and pharmacodynamics
PT5-04 Preclinical toxicity
PT5-05 Other

PT6 Therapeutic Agents I: Small Molecule Approaches
PT6-01 Alkylating agents
PT6-02 Antifolates
PT6-03 Chemopreventive therapeutic agents
PT6-04 Ether lipids
PT6-05 Farnesyl transferase inhibitors
PT6-06 Novel antitumor agents
PT6-07 Oncogene-based therapeutics: small molecules
PT6-08 Platinum complexes
PT6-09 Tyrosine kinase and phosphatase inhibitors
PT6-10 Other

PT7 Therapeutic Agents II: Biological Approaches
PT7-01 Antireceptors
PT7-02 Antisense oligonucleotides
PT7-03 Anti viral therapy
PT7-04 Apoptosis: therapeutic manipulation
PT7-05 Growth factor receptors and other surface antigens as targets for therapy
PT7-06 Other

PT7-07 Protein kinases and phosphatases as targets for therapy
PT7-08 Other

PT8 Experimental Gene Therapy
PT8-01 Vector systems and targeting strategies
PT8-02 Cell-type targeted vectors
PT8-03 TK-based suicide gene therapy
PT8-04 Cell-type specific expression regulation of suicide genes
PT8-05 Antisense/ribozyme decoys
PT8-06 Delivery systems: nonbiological, e.g., liposomes
PT8-07 Hematopoietic progenitor cell targeting
PT8-08 Other

PT9 Topoisomerases, Other DNA-Reactive Agents, and Tubulin Agents
PT9-01 DNA-reactive agents
PT9-02 Topoisomerases
PT9-03 Tubulin agents
PT9-04 Other

RR RADIATION ONCOLOGY

Experimental Radiation Biology
RR1-01 ATM: structure-function
RR1-02 ATM: genomic aspects and mutations
RR1-03 Cell cycle, differentiation, and apoptosis in radiation responses
RR1-04 Cytogenetic responses to radiation
RR1-05 DNA damage, mutagenesis, and repair
RR1-06 Experimental radiotherapeutics
RR1-07 Genetic and epigenetic control of radiosensitivity
RR1-08 Hyperthermia
RR1-09 Membrane targets for radiation
RR1-10 Molecular mechanisms/radiation-induced gene expression
RR1-11 Photobiology
RR1-12 Photodynamic therapy
RR1-13 Predictive assays for radiation sensitivity
RR1-14 Oncogenes and tumor suppressor genes in radiation responses
RR1-15 Radiation-induced biochemical alterations: conformation and function
RR1-16 Radiation-induced transformation and carcinogenesis
RR1-17 Radiation resistance
RR1-18 Radiolabelled antibodies in diagnosis and localization
RR1-19 Radioprotectors and radiosensitizers
RR1-20 Tumor oxygenation and modification
RR1-21 Radiation Oncology: Preclinical and Clinical
RR1-22 Clinical radiotherapeutic studies
RR1-23 Combination therapies
RR1-24 Drug-radiation interactions
RR1-25 Modification of radiation sensitivity and injury
RR1-26 Radiation-induced late effects — second cancers
RR1-27 Radiation resistance
RR1-28 Radiolabelled antibodies in diagnosis and localization
RR1-29 Radioprotectors and radiosensitizers
RR1-30 Other
COPYRIGHT TRANSFER/CONFLICT OF INTEREST DISCLOSURE FORM

Your abstract cannot be considered unless this form is completed, signed, and enclosed with your submitted abstract.

NAME OF PRESENTER:

TITL E OF ABSTRACT:

COPYRIGHT TRANSFER

As the PRESENTER and as an author of this abstract, on behalf of all the authors (check appropriate box and affix signature):

☐ I hereby transfer copyright of this abstract to the American Association for Cancer Research (AACR), Inc., in the event that this abstract is published in the Proceedings of the American Association for Cancer Research. I understand by this transfer that the authors relinquish all exclusive rights of copyright ownership to the abstract, including without limitation all rights of reproduction, derivation, distribution, sale, and display of the work, in whole or in part, in any and all forms of media now or hereafter known. I understand the AACR, Inc., as copyright owner, has sole authority to grant permission to reproduce the abstract.

☐ This abstract was prepared by an employee or employees of the United States Federal Government. Therefore, I am unable to transfer rights to AACR, Inc.

Signature of Presenter __________________________ Date __________________________

DISCLOSURE STATEMENT FOR CONTINUING MEDICAL EDUCATION FACULTY

The American Association for Cancer Research (AACR) is committed to ensuring the integrity of its scientific, educational, and research programs and therefore requires disclosure of any financial or other interests which might be construed as resulting in an actual, potential, or apparent conflict. The existence of financial interests or other relationships of a commercial nature is not regarded by the AACR as creating a presumption of impropriety. Rather, AACR's policy represents a recognition of the many factors that can influence judgments about research data and a desire to make as much information as possible available to those reviewing the data.

All faculty participating in an educational activity are expected to disclose to the activity audience any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/ or provider(s) of commercial services discussed in an educational presentation. (Significant financial interest or other relationship can include such things as grants or research support, employee, consultant, major stockholder, member of speakers bureau, etc.) The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion.

The PRESENTER is responsible for providing disclosure information for the PRESENTER and all CO-AUTHORS listed on the abstract. The PRESENTER'S signature verifies that all authors have read the Disclosure Statement and that appropriate disclosures have been documented.

I. a. Will your presentation/abstract include discussion of any commercial products or services? Yes ___ No ___

b. If Yes, do you or any of your co-authors have a significant financial interest or other relationship with the manufacturer(s) of any of the products or provider(s) of any of the services you intend to discuss? Yes ___ No ___

If Yes, please list the manufacturer(s) or provider(s) and describe the nature of the relationship(s). (Attach additional sheets as required.)

<table>
<thead>
<tr>
<th>Author/Co-author Name</th>
<th>Company Name</th>
<th>Nature of Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

II. Will the presentation/abstract include information about unlabeled or investigational uses of commercial products? Yes ___ No ___

If Yes, please identify the commercial products and unlabeled or investigational uses. (Attach additional sheets as required.)

<table>
<thead>
<tr>
<th>Product</th>
<th>Unlabeled/Investigational Use(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Submitted by: __________________________ Fax# __________________________
(Print or Type Name)                      Date __________________________

Signature ___________________________
ABSTRACT FORM

AACR Annual Meeting
April 10-14, 1999
Philadelphia, PA

Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Wattenberg, L.W., Wiedmann, T.S., Estensen, R.D., Zimmerman, C.L., Steele, V.E., and Kellogg, G.J. *University of Minnesota, Minneapolis, MN 55455 and National Cancer Institute, Bethesda, MD 20892*

This study is part of an effort to develop effective chemoprevention for carcinogenesis of the lung. The present study explores aerosol administrations for this purpose. The agent selected for study is the synthetic glucocorticoid, budesonide. A nose-only aerosol technique has been developed which entails nebulization of budesonide dissolved in ethanol and subsequent stripping off the solvent. The size range of the budesonide particles produced by the apparatus has a mass median aerodynamic diameter of less than 1 μm. An experiment in which the inhibition of the induced lung neoplasia, given for 1 minute, 6 times a week has been carried out. Concentrations of budesonide of 26, 81 and 148 μg/liter of air (calculated doses of 23, 72 and 126 μg/Kg body weight) were used. The aerosols were started 1 week after 3 oral administrations of benzo[a]pyrene 2 mg/20Gm body weight to female A/J mice. All 3 doses of budesonide resulted in over 80% inhibition of pulmonary tumor formation, as compared to the aerosol control, and 90% or greater compared to mice not exposed to aerosol. The difference in inhibition is due to the aerosol procedure itself producing a reduction in tumor formation. A decrease in splenic weight (evidence of a systemic effect) occurred at all doses of budesonide. To the best of our knowledge, this is the first published effort at the use of aerosol administrations to prevent neoplasia of the lung. The results show that administration of budesonide by aerosol can prevent pulmonary carcinogenesis in female A/J mice.

Type abstract within black lines. See sample abstract.

2. Abstract is SPONSORED by: 3676 Member No. (See Directory of Members for Member No.)
Lee W. Wattenberg Name
Dept. of Lab. Med. & Pathology Address 321 Church St. SE, Jackson 6-133
Minneapolis, MN City, State 55455 Zip/Postal Code USA Country
(612) 625-1443 Telephone No. (612) 625-1447 FAX No.
watte02@maroon.tc.umn.edu E-Mail Address

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein.

Lee W. Wattenberg Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus Member, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 5.)

Lee W. Wattenberg Name

5. Eligibility for Annual Meeting Awards (American and International)

A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.
B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 7).
C. The PRESENTER of this abstract is a full-time faculty member at a Historically Black College or University (HBCU).

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US$40 which will be billed to the SPONSOR.

6. Abstract is to be PRESENTED by: 3676 Member No. (If an AACR Member)
Lee W. Wattenberg Name
Dept. of Lab. Med. & Pathology Address 321 Church St. S.E., Jackson 6-133
Minneapolis, MN City, State 55455 Zip/Postal Code USA Country
(612) 625-1443 Telephone No. (612) 625-1447 FAX No.
watte02@maroon.tc.umn.edu E-Mail Address

7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1999 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original and 1 copy of the Copyright Transfer/Confidential Interest Disclosure Form.

Lee W. Wattenberg Signature of PRESENTER


X Check is enclosed. Please list name of PRESENTER on the check.
I authorize you to charge my credit card for the abstract submission fee.

VISA MasterCard American Express
Card No. Expiration Date

Cardholder Name (PRINT) Signature
Deadline: November 6, 1998

Enclose:

Original abstract form plus 3 photocopies. (This form must be filled out completely. Requested signatures must appear on all copies.)

- Check for US$40 payable to AACR, Inc., OR authorization to charge US$40 to credit card (see Item 8, below).
- A completed and signed original plus 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form
- Acknowledgment Card (completed and stamped).
- A self-addressed, stamped envelope.

1. Category and Subclassification (see Pages 10-12): Type the five-character code in the blocks provided, for example,

   [ ]  [ ]  [ ]  [ ]  [ ]

   [ ]  [ ]  [ ]  [ ]  [ ]

   Type abstract within black lines. See sample abstract.

2. Abstract is SPONSORED by: ____________________________
   (See Directory of Members for Member No.)
   Name ____________________________
   (Please Print)
   Address ____________________________
   City, State ____________________________
   Zip/Postal Code ____________________________
   Telephone No. ____________________________
   FAX No. ____________________________
   E-Mail Address ____________________________

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein.

   Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus Member, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 5.)

   Name ____________________________
   (Please Print)
   Signature ____________________________
   Member No. ____________________________

5. Eligibility for Annual Meeting Awards (American and International)
   □ A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.
   □ B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 7).
   □ C. The PRESENTER of this abstract is a full-time faculty member at a Historically Black College or University (HBCU).

   Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US$40 which will be billed to the SPONSOR.

6. Abstract is to be PRESENTED by: ____________________________
   (If an AACR Member.)
   Name ____________________________
   (Please Print)
   Address ____________________________
   City, State ____________________________
   Zip/Postal Code ____________________________
   Telephone No. ____________________________
   FAX No. ____________________________
   E-Mail Address ____________________________

7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1999 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original and 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form.

   Signature of PRESENTER


   Check is enclosed. Please list name of PRESENTER on the check.
   □ I authorize you to charge my credit card for the abstract submission fee.

   Card No. ____________________________
   Expiration Date ____________________________
   Cardholder Name (PRINT) ____________________________
   Signature ____________________________
**ABSTRACT FORM**

**AACR Annual Meeting**  
April 10-14, 1999  
Philadelphia, PA

---

**Deadline: November 6, 1998**  
**Enclose:**  
- Original abstract form plus 3 photocopies. (This form must be filled out completely. Requested signatures must appear on all copies.)  
- Check for US$40 payable to AACR, Inc., OR authorization to charge US$40 to credit card (see item 8, below).  
- A completed and signed original plus 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form  
- Acknowledgment Card (completed and stamped).  
- A self-addressed, stamped envelope.

---

1. **Category and Subclassification**  
   (see Pages 10-12): Type the five-character code in the blocks provided, for example,

   - [ ] [ ] [ ] [ ]

   - [ ] [ ] [ ] [ ]

2. **Abstract is SPONSORED by:**  
   **Member No.**  
   **(See Directory of Members for Member No.)**  
   **Name**  
   **(Please Print)**  
   **Address**

   **City, State**

   **Zip/Postal Code**  
   **Country**  
   **Telephone No.**  
   **FAX No.**

   **E-Mail Address**

3. **As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein.**  
   **Signature of SPONSOR**

4. **(Complete only if SPONSOR is an Associate Member)**  
   I, the undersigned Active or Corresponding Member in good standing, Emeritus Member, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 5.)  
   **(Please Print)**  
   **Name**

   **Signature**  
   **Member No.**

5. **Eligibility for Annual Meeting Awards (American and International)**  
   - [ ] A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.
   - [ ] B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 7).  
   - [ ] C. The PRESENTER of this abstract is a full-time faculty member at a Historically Black College or University (HBCU).

---

6. **Abstract is to be PRESENTED by:**  
   **Member No.**  
   **(If an AACR Member.)**  
   **Name**  
   **(Please Print)**  
   **Address**

   **City, State**

   **Zip/Postal Code**  
   **Country**  
   **Telephone No.**  
   **FAX No.**

   **E-Mail Address**

7. **As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1999 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original and 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form.**  
   **Signature of PRESENTER**

---

8. **Payment of US$40 Abstract Submission Fee.**  
   _Check is enclosed. Please list name of PRESENTER on the check._

   _I authorize you to charge my credit card for the abstract submission fee._

   - [ ] VISA  
   - [ ] MasterCard  
   - [ ] American Express

   **Card No.**  
   **Expiration Date**

   **Cardholder Name (PRINT)**  
   **Signature**

---

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US$40 which will be billed to the SPONSOR.
BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 13,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
3. an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. reduced registration rates at annual meetings;
5. priority notice of small, focused meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
6. substantially reduced registration rates for Special Conferences;
7. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
8. receipt of AACR Newsletters and other important announcements;
9. early notification of and reduced rates for participation in the AACR Employment Register;
10. an up-to-date Membership Directory of over 13,500 member researchers in the cancer field;
11. the professional benefits of AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
12. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
13. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
14. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application:

January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

Receipt of Application
in AACR Office  Notification of Candidate
January 1         March
May 1            July
September 1      November

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. —OR— The nominator may sign the application form where indicated under the heading, "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). —OR— The seconder may sign the application form where indicated under the heading, "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded. All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West • Philadelphia, PA 19106-3483
Phone: 215/440-9300 • FAX: 215/440-9412
E-mail: membership@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1999 annual dues for active members are $185, $105 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues ($105 in 1999) and, may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
**Application for Active or Corresponding Membership**

<table>
<thead>
<tr>
<th>NAME OF CANDIDATE:</th>
<th>DATE OF BIRTH:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRESENT POSITION/TITLE:</th>
<th>M. I.</th>
<th>Month / Day / Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INSTITUTIONAL AFFILIATION:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INSTITUTIONAL ADDRESS:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TELEPHONE NUMBER:</th>
<th>FAX NUMBER:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(If outside the United States list country and city codes.)

<table>
<thead>
<tr>
<th>PRIMARY FIELD OF RESEARCH (Please check only one):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biochemistry and Biophysics</td>
</tr>
<tr>
<td>Biostatistics</td>
</tr>
<tr>
<td>Cellular Biology and Genetics</td>
</tr>
<tr>
<td>Clinical Investigations</td>
</tr>
<tr>
<td>Epidemiology</td>
</tr>
<tr>
<td>Immunology</td>
</tr>
<tr>
<td>Molecular Biology and Genetics</td>
</tr>
<tr>
<td>Virology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ACADeMIC DEGREES (Including where and when granted)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CANDIDATE IS APPLYING FOR (Check one):</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Active Membership</td>
</tr>
<tr>
<td>☐ Corresponding Membership</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CANDIDATE NOMINATED BY*:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Please print)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CANDIDATE SECONDED BY*:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Please print)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STATEMENT OF SUPPORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>I acknowledge by signing this statement of support, that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.</td>
</tr>
</tbody>
</table>

Signature of Nominator:  
Date:  

Signature of Seconder:  
Date:  

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be Active, Corresponding, Emeritus, or Honorary members of the AACR in good standing.*
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who signs the abstract does not lose his or her own sponsorship privilege);
2. optional subscriptions to the Association’s high-quality journals: Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates; beginning in 1998 associate members will be able to purchase AACR journals for half the price of a regular member subscription;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. the privilege of electing an Associate Member Council that organizes programs benefiting associate members and that presents their concerns to the AACR Board of Directors;
5. the opportunity to stand for election to the Associate Member Council;
6. preferred access to the AACR Employment Register;
7. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
8. substantially reduced registration rates at special conferences;
9. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
10. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
11. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues for 1998 and 1999 are $55 for associate members residing in the Americas and $65 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
Email: membership@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1998 and 1999 have been set at $55 per year for residents of the Americas and $65 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1998 for the forthcoming annual meeting must have paid dues for 1998. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1999 may retain associate membership until December 31, 2003. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D. Executive Director

21
NAME OF CANDIDATE: ____________________________

DATE OF BIRTH: ____________________________

INSTITUTIONAL AFFILIATION:

INSTITUTIONAL ADDRESS:

(City) ____________________________ (State/Province) ____________________________ (Country) ____________________________ (Postal Code) ____________________________

TELEPHONE NUMBER: ____________________________ FAX NUMBER: ____________________________

E-MAIL ADDRESS: ____________________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one):

□ Graduate Student □ Medical Student □ Physician in Training □ Postdoctoral Fellow

Gender: □ Male □ Female

PRIMARY FIELD OF RESEARCH (Please check only one):

□ Biochemistry and Biophysics □ Biostatistics □ Carcinogenesis
□ Cellular Biology and Genetics □ Clinical Investigations □ Endocrinology
□ Epidemiology □ Immunology □ Molecular Biology and Genetics
□ Preclinical Pharmacology and □ Virology □ Other: ____________________________ Experimental Therapeutics

(If outside the United States list country and city codes.)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY*:

(Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: ____________________________ Date: ____________________________

I recommend this candidate for Associate Membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: ____________________________ Date: ____________________________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. For 1998 and 1999 dues are $55 for Associate Members residing in the Americas and $65 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

☐ Current calendar year ☐ Forthcoming calendar year

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be Active, Corresponding, Emeritus, or Honorary member of the AACR in good standing.

(This form may be reproduced.)

1999
AMERICAN ASSOCIATION FOR CANCER RESEARCH
90TH ANNUAL MEETING
April 10-14, 1999 • Philadelphia, Pennsylvania

Hotel Reservations

Reserve Early! Deadline – March 12, 1999

GENERAL INFORMATION

The AACR Housing Bureau will handle all housing needs for the Philadelphia meeting. Participating hotels will not honor direct reservations, and published room rates apply only to rooms reserved through the AACR Housing Bureau.

LIST OF HOTELS

All hotels holding rooms for AACR Annual Meeting attendees are described on the following pages. Please see the hotel map which shows the locations of the hotels being used in Center City Philadelphia.

Hotels at the Philadelphia Airport are approximately 15-20 minutes by bus from the Pennsylvania Conventions Center.

Hotels on City Line Avenue (Adam’s Mark and Holiday Inn City Line) are approximately 20-30 minutes by bus from the Pennsylvania Convention Center.

AACR will provide frequent complimentary shuttle bus service between airport hotels and the Convention Center, between City Line Avenue hotels and the Convention Center, and between Center City hotels (except the adjacent Marriott) and the Convention Center.

HOTEL DEPOSIT

A $150.00 deposit is required in order to reserve a room. The deposit may be made by credit card or check. YOUR CREDIT CARD WILL BE CHARGED IMMEDIATELY. Acceptable credit cards are American Express, Visa, MasterCard, Eurocard, and Discover. Make checks payable to WRI/AACR Housing Bureau.

HOTEL CHANGES AND CANCELLATIONS

If you are unable to attend the Annual Meeting, please cancel your reservation as soon as possible to allow the room to be reserved by another attendee. All changes and cancellations must be made by contacting the AACR Housing Bureau. For a refund of the deposit, the reservation must be cancelled according to the hotel’s cancellation policy which is, in most cases, 72 hours prior to scheduled arrival. Please verify the hotel’s cancellation policy on the reservation confirmation to make sure that no special conditions apply.

FOUR EASY WAYS TO RESERVE HOTEL ACCOMMODATIONS

WEB Reserve a room by visiting the AACR website at www.aacr.org. Attendees who reserve rooms over the Internet will receive an e-mail confirming transmission and a room confirmation by mail. Also visit the website to print an AACR Official Housing Form.

FAX Complete the AACR Official Housing Form enclosed in this booklet and fax to:
1-972-349-7715 (U.S. and International)

PHONE Have the completed AACR Official Housing Form and a credit card ready before calling:
Toll Free (U.S. only): 1-888-447-2319
International: 1-972-349-7409

Hours of operation are 8:00 a.m. – 6:00 p.m. (Central Standard Time)

MAIL Complete the AACR Official Housing Form enclosed in this booklet and return it with credit card information or a check made payable to WRI/AACR to:
AACR Housing Bureau
P.O. Box 864906
Plano, TX 75086-4906
# OFFICIAL HOUSING FORM

**RESERVATION DEADLINE:** MARCH 12, 1999

One form per room

If more than one form is needed, this form may be duplicated or printed off the internet (www.aacr.org).

- New Reservation
- Change
- Cancellation

**FAMILY NAME**

<table>
<thead>
<tr>
<th>FIRST NAME</th>
<th>MI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ADDRESS**

<table>
<thead>
<tr>
<th>CITY</th>
<th>STATE</th>
<th>POSTAL CODE</th>
<th>COUNTRY (if not U.S.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DAYTIME TELEPHONE**

<table>
<thead>
<tr>
<th>FAX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

## HOTEL PREFERENCE

<table>
<thead>
<tr>
<th>Map #</th>
<th>Hotel Name:</th>
<th>Map #</th>
<th>Hotel Name:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
<td>3.</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td>4.</td>
<td></td>
</tr>
</tbody>
</table>

If none of your hotels are available, which is most important?

- LOCATION
- PRICE
- TYPE OF HOTEL

**ARRIVAL DATE:** April ____________

**DEPARTURE DATE:** April ____________

## ROOM TYPE

- **SINGLE**: 1 person – 1 bed
- **DOUBLE**: 2 people – 1 bed
- **DOUBLEx2**: 2 people – 2 dbl. beds
- **TRIPLE**: 3 people – 2 dbl. beds
- **QUAD**: 4 people – 2 dbl. beds
- **SUITE**: 1 – 2 bedrooms (circle one)

**Number of persons _______**

List names of people you are sharing a room with:

(First & Last Name)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RESERVATION DEPOSIT** All hotels require a first night’s deposit of $150.00 to guarantee each room reservation. Credit cards will be charged immediately. If paying by check, make payable to WRI/AACR Housing Bureau. Checks must be in U.S. dollars and drawn on a U.S. bank. Checks must be received within 15 days or the reservation will be cancelled.

## SPECIAL REQUESTS:

- King Bed
- Rollaway
- Non-Smoking
- Smoking

**Do You Require Special Assistance?**

- If you have a disability and require accommodations, please check here and attach a statement regarding your disability-related needs. We cannot assure the availability of appropriate accommodations without prior notification of need.

## CANCELLATIONS

Hotel cancellation policies vary. Contact the AACR Housing Bureau to confirm your hotel's policy.

## METHODS OF PAYMENT

- Check or money order enclosed
- VISA
- MasterCard
- American Express
- Discover

<table>
<thead>
<tr>
<th>Card Number</th>
<th>Exp. Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Signature of cardholder

**RETURN TO:**

FAX form to: 1-972-349-7715

- OR - MAIL form to: AACR Housing Bureau
  P.O. Box 864906
  Plano, TX 75086-4906

Reservations can also be made by visiting the AACR website (www.aacr.org) or by calling toll free 1-888-447-2319 (in the U.S.)—or—1-972-349-7409 (international) from 7:00am – 7:00pm, CST.
**HOTELS IN PHILADELPHIA, PENNSYLVANIA RESERVING ROOMS FOR AACR REGISTRANTS**

<table>
<thead>
<tr>
<th>Map Number</th>
<th>Hotel Name</th>
<th>Special Accommodations</th>
<th>Single</th>
<th>Double</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Philadelphia Marriott (Headquarters Hotel)</td>
<td></td>
<td>$189</td>
<td>$209</td>
</tr>
<tr>
<td>2</td>
<td>Adam's Mark</td>
<td></td>
<td>$196</td>
<td>$212</td>
</tr>
<tr>
<td>3</td>
<td>Airport Hilton</td>
<td></td>
<td>$126</td>
<td>$126</td>
</tr>
<tr>
<td>4</td>
<td>Airport Marriott</td>
<td></td>
<td>$165</td>
<td>$165</td>
</tr>
<tr>
<td>5</td>
<td>Best Western Center City</td>
<td></td>
<td>$89</td>
<td>$99</td>
</tr>
<tr>
<td>6</td>
<td>Best Western Independence Park</td>
<td></td>
<td>$115</td>
<td>$125</td>
</tr>
<tr>
<td>7</td>
<td>Clarion Suites</td>
<td></td>
<td>$129</td>
<td>$139</td>
</tr>
<tr>
<td>8</td>
<td>Comfort Inn Downtown</td>
<td></td>
<td>$109</td>
<td>$119</td>
</tr>
<tr>
<td>9</td>
<td>Crowne Plaza Center City</td>
<td></td>
<td>$149</td>
<td>$163</td>
</tr>
<tr>
<td>10</td>
<td>Doubletree Hotel</td>
<td></td>
<td>$169</td>
<td>$189</td>
</tr>
<tr>
<td>11</td>
<td>Embassy Suites Center City</td>
<td></td>
<td>$152</td>
<td>$152</td>
</tr>
<tr>
<td>12</td>
<td>Embassy Suites Airport</td>
<td></td>
<td>$129</td>
<td>$129</td>
</tr>
<tr>
<td>13</td>
<td>Four Points Sheraton</td>
<td></td>
<td>$99</td>
<td>$99</td>
</tr>
<tr>
<td>14</td>
<td>Four Seasons</td>
<td></td>
<td>$237</td>
<td>$237</td>
</tr>
<tr>
<td>15</td>
<td>Hawthorn Suites</td>
<td>Studio, 1-br suite</td>
<td>$119</td>
<td>$129</td>
</tr>
<tr>
<td>16</td>
<td>Holiday Inn Airport</td>
<td></td>
<td>$110</td>
<td>$110</td>
</tr>
<tr>
<td>17</td>
<td>Holiday Inn City Line</td>
<td></td>
<td>$119</td>
<td>$119</td>
</tr>
<tr>
<td>18</td>
<td>Holiday Inn Express</td>
<td></td>
<td>$110</td>
<td>$115</td>
</tr>
<tr>
<td>19</td>
<td>Holiday Inn Independence Mall</td>
<td></td>
<td>$134</td>
<td>$144</td>
</tr>
<tr>
<td>20</td>
<td>Holiday Inn Stadium</td>
<td></td>
<td>$129</td>
<td>$129</td>
</tr>
<tr>
<td>21</td>
<td>Korman Suites</td>
<td>Studio</td>
<td>$135</td>
<td>$155</td>
</tr>
<tr>
<td>22</td>
<td>Latham</td>
<td></td>
<td>$145</td>
<td>$165</td>
</tr>
<tr>
<td>23</td>
<td>Omni Independence Park</td>
<td></td>
<td>$199</td>
<td>$219</td>
</tr>
<tr>
<td>24</td>
<td>Park Hyatt Philadelphia at the Bellevue</td>
<td></td>
<td>$180</td>
<td>$180</td>
</tr>
<tr>
<td>25</td>
<td>Radisson Airport</td>
<td></td>
<td>$155</td>
<td>$155</td>
</tr>
<tr>
<td>26</td>
<td>Ritz Carlton</td>
<td></td>
<td>$182</td>
<td>$182</td>
</tr>
<tr>
<td>27</td>
<td>Sheraton Society Hill</td>
<td></td>
<td>$177</td>
<td>$197</td>
</tr>
<tr>
<td>28</td>
<td>Sheraton University City</td>
<td></td>
<td>$134</td>
<td>$134</td>
</tr>
<tr>
<td>29</td>
<td>The Warwick</td>
<td></td>
<td>$146</td>
<td>$156</td>
</tr>
<tr>
<td>30</td>
<td>Westin Suites Airport</td>
<td></td>
<td>$129</td>
<td>$129</td>
</tr>
<tr>
<td>31</td>
<td>Windsor</td>
<td></td>
<td>$125</td>
<td>$125</td>
</tr>
<tr>
<td>32</td>
<td>Wyndham Franklin Plaza</td>
<td></td>
<td>$169</td>
<td>$189</td>
</tr>
</tbody>
</table>

Triple and Quad Rates are Available Upon Request.
All Rates Are Subject to State and Local Taxes Totaling 13%. 

26
1. PHILADELPHIA MARRIOTT (Headquarters Hotel)
The Marriott is connected directly to the Pennsylvania Convention Center and is next to the Gallery Mall. This hotel, standing in the hub of the business and historic districts, has three restaurants offering menus for any guest’s taste. Twenty-four hour room service is also available. Facilities include an indoor lap pool, exercise room, aerobics room, whirlpool, and sauna. The Philadelphia Marriott is only eight miles from Philadelphia International Airport and is easily accessible to major interstates and the train station. Guest rooms have upgraded amenities, and health-club facilities, including cardiovascular equipment, are available.
Rates:  
Single $189  
Double $209

2. ADAM’S MARK
The Adam’s Mark is minutes away from historic Philadelphia, the Philadelphia Art Museum, and the Franklin Institute. Famous restaurants include the Marker and Appleby’s, the Player’s Sports Bar and the popular nightclub Quincy’s/Philadelphia. Indoor/outdoor pools, a well-equipped health club, and free parking are available. Convenient to the Pennsylvania Turnpike, Amtrak’s 30th Street Station, and Philadelphia International Airport.
Rates:  
Single $196  
Double $212

3. AIRPORT HILTON
The Airport Hilton Features 331 guest rooms with large desks, climate control, cable TV, HBO, and complimentary newspaper. Guest can enjoy an indoor pool, whirlpool, and health club. Located across from the Philadelphia International Airport, the Hilton provides complimentary airport shuttle and free parking.
Rates:  
Single/Double $126

4. AIRPORT MARRIOTT
The Marriott opened its doors in 1995. Conveniently located off I-95 and the High Speed Rail Line, the hotel features a unique skybridge connecting the hotel to the Philadelphia International Airport. Additional hotel amenities include the Riverbend Bar and Grill, Concierge Lounge, an indoor lap pool, and an exercise room.
Rates:  
Single/Double $165

5. BEST WESTERN CENTER CITY
From our doors you can walk to the Philadelphia Museum of Art, the Rodin Museum, the Franklin Institute Science Museum, and the Academy of Natural Sciences. We are just minutes from the Pennsylvania Convention Center, the Liberty Bell, Philadelphia Zoo and many of Philadelphia’s finest restaurants. Outdoor pool, fitness center, and free parking are available.
Rates:  
Single $89  
Double $99

6. BEST WESTERN INDEPENDENCE PARK
Philadelphia’s great little hotel, set in the heart of “America’s most historic square mile,” the Best Western Independence Park is centrally located near Penn’s Landing, the Liberty Bell, Franklin Court, Society Hill, and Independence Mall and housed in a historically certified Victorian building. Complimentary European breakfast is served daily.
Rates:  
Single $115  
Double $125

7. CLARION SUITES
This historically registered hotel is located one-half block from the Pennsylvania Convention Center and the Gallery shopping mall, and six blocks from all historical attractions. Large suites feature full kitchen, two televisions, and more. The hotel features an intimate lobby lounge, a café, and a fitness room. Free deluxe continental breakfast daily.
Rates:  
Single $129  
Double $139

8. COMFORT INN DOWNTOWN
The Comfort Inn features many rooms with waterfront and city views, complimentary deluxe continental breakfast, on-site parking, and courtesy van service to area restaurants, attractions, hospitals, and the Pennsylvania Convention Center. The hotel is within walking distance to the Liberty Bell, Betsy Ross House, Independence Mall, Independence Seaport Museum, and Penn’s Landing Park, and a ferry ride away from the New Jersey State Aquarium at Camden.
Rates:  
Single $109  
Double $119

9. CROWNE PLAZA CENTER CITY
The Crowne Plaza offers a central location in the heart of one of the largest commercial, cultural, and historical centers in the country. The Pennsylvania Convention Center is only six blocks away. The hotel features the Elephant & Castle Pub & Restaurant serving breakfast, lunch, dinner and late-night snacks, along with a lobby espresso bar, The E&C Express.
Rates:  
Single $149  
Double $163

10. DOUBLETREE HOTEL
The Doubletree is within walking distance of the Pennsylvania Convention Center, just one mile from Amtrak’s 30th Street Station and 20 minutes from the Philadelphia International Airport. Spacious guest rooms with a panoramic view of the city are across the street from the Academy of Music, the Merriam Theater, and adjacent to the Wilma Theater. The hotel features an indoor swimming pool, two racquetball courts, a roof garden with a jogging track, whirlpool, saunas, and steam rooms.
Rates:  
Single $169  
Double $189

11. EMBASSY SUITES CENTER CITY
The Embassy Suites Center City is located on Logan Square in the heart of the city’s cultural center and within walking distance to all of Center City and the Pennsylvania Convention Center. All suites have a living room, kitchen area with refrigerator, wet bar, microwave, and coffee makers, and a separate bedroom with television. Free breakfast buffet each morning and beverages at the manager’s reception each evening. The hotel also has a 24-hour fitness room and sauna.
Rates:  
Single/Double $152

12. EMBASSY SUITES AIRPORT
This all-suite hotel is conveniently located one mile from the Philadelphia International Airport. Complimentary breakfast and a two-hour manager’s reception are included with every stay. Indoor pool and workout room are available. Complimentary shuttle service to and from the airport.
Rates:  
Single/Double $129

13. FOUR POINTS SHERATON
At the Four Points Sheraton, you can take a swim in our outdoor pool or head outside for some exercise on our jogging trail. For dining, there’s the trendy Newstand Café, open for breakfast, lunch, or dinner. Located adjacent to Philadelphia International Airport, the Four Points Hotel is just minutes from Center City Philadelphia. Complimentary airport shuttle is also available.
Rates:  
Single/Double $99

14. FOUR SEASONS
The proximity to the city’s premier cultural attractions and the Pennsylvania Convention Center makes the Four Seasons Hotel an ideal location. Features include a full-service spa/health club, indoor pool, the Fountain Restaurant, one of the nation’s most acclaimed restaurants, exquisite Sunday brunch, and the Swan Lounge Viennese dessert buffet. Live music Thursday through Saturday.
Rates:  
Single/Double $237

15. HAWTHORN SUITES
The Hawthorn Suites Hotel is located directly adjacent to the Pennsylvania Convention Center at 11th and Vine Streets. This all-suite hotel offers spacious studio and one-bedroom suites. All units have efficiency kitchens that feature a microwave, refrigerator, wet bar area, and coffee maker. Included in the group rate is a daily complimentary full breakfast buffet and social hour Monday through Thursday. Other features and amenities include: dual phone lines, convenient laptop hookup, exercise room, on-site convenience store, free HBO, free daily newspaper, free local phone calls, and valet parking.
Rates:  
Studio $119  
1-br suite $129

16. HOLIDAY INN AIRPORT
The Holiday Inn Philadelphia International Airport is located 3 miles south of Philadelphia International Airport. The hotel features an executive floor, seasonal pool, health facility, and complimentary 24-hour airport transfer. Landings Bar and Grille serves breakfast, lunch, and dinner, and Room Service is available until 11PM. Each room includes a hair dryer, coffee maker, iron, and ironing board.
Rates:  
Single/Double $110
HOTEL DESCRIPTIONS

17. HOLIDAY INN CITY LINE
The Holiday Inn City Line is located in a lovely suburban-like location just northwest of Center City Philadelphia. What makes this location nice is that City Avenue divides Philadelphia from its affluent surrounding neighborhoods and distinguished universities. Free parking, indoor/outdoor pool, and more.
Rates: Single/Double $119

18. HOLIDAY INN EXPRESS
The Holiday Inn Express offers a free deluxe breakfast bar and complimentary local phone calls. The midtown location is within walking distance from historic and cultural attractions, shopping, and the Pennsylvania Convention Center. Easy access to Philadelphia International Airport, Amtrak's 30th Street Station, Sports Complex, and all major highways. Other amenities include self-parking, valet parking, and free access to Bally's Total Fitness Center.
Rates: Single $110 Double $115

19. HOLIDAY INN INDEPENDENCE MALL
The Holiday Inn Independence Mall is located in the heart of the nation's "most historic square mile," within two blocks are Independence Mall, the Liberty Bell, the Betsy Ross House, Franklin Court and the U.S. Mint. Also, it is just three blocks from Penn's Landing and waterfront events. Holiday Inn Independence Mall offers beautifully appointed rooms, the convenience of two restaurants, a lounge, room service, and a gift shop.
Rates: Single $134 Double $144

20. HOLIDAY INN STADIUM
The Holiday Inn Stadium is conveniently located just ten minutes away from the Philadelphia International Airport and only five minutes to Philadelphia's Business and Historic districts. Our amenities include hair dryers and ironing boards in each room. We offer breakfast, lunch, and dinner at our beautiful full service restaurant "Jaws", and spirited libations, your favorite sandwich, and favorite sporting event at our sports bar "Philly Legends." Plenty of complimentary parking is available to all our guests.
Rates: Single/Double $129

21. KORMAN SUITES
This unique hotel has spacious guest suites in the heart of Philadelphia's museum/cultural district and is within walking distance to nightlife and all of Center City. Each room features a microwave, coffee maker, and refrigerator. Spectacular city views, a full-service fitness center, complimentary covered parking, and complimentary shuttle service are available. Also featured is The Grill at Catalina, which offers outstanding Italian cuisine.
Rates: Studio $135 Double $155

22. LATHAM
Located in the heart of Center City, this European-style boutique hotel is known for its intimate, understated elegance and personalized service. Added amenities include nightly turn-down service, imported chocolates, HBO, CNN, ESPN, and in-room movies. Complimentary health-club facilities are available.
Rates: Single $145 Double $165

23. OMNI INDEPENDENCE PARK
This luxury hotel is located in the heart of Independence National Historic Park. All rooms have a dramatic view of the park, minibar, and two phones with computer/fax capabilities. The Omni is within walking distance to Independence Mall, the Liberty Bell, Penn's Landing and trendy South Street. The critically acclaimed Azalea Restaurant invites you to experience award-winning creative regional cuisine.
Rates: Single $199 Double $219

24. PARK HYATT PHILADELPHIA AT THE BELLEVUE
This intimate four-star, four-diamond hotel features French Renaissance architecture crowning the top floors of the restored Bellevue Building. Luxurious guest rooms and suites feature 14-foot ceilings, American Empire-style furnishings, marble baths, and 24-hour room service, as well as a European-style concierge and turn-down service. Enjoy the award-winning Founders Dining Room or English afternoon tea. Spa/salon, fitness club, retail shops, food court, offices, and parking garage are also housed within the complex. The hotel is located downtown on the Avenue of the Arts in the heart of the city's theater and cultural district.
Rates: Single/Double $180

25. RADISSON AIRPORT
The Radisson is conveniently located only one mile from the Philadelphia International Airport and easily accessible via Interstates 95, 76 and Routes 291 & 476. A health/fitness area with indoor swimming pool, whirlpool, and exercise equipment are featured in the hotel. The Chesapeake Grille Restaurant offers delicious meals from breakfast through dinner in a contemporary setting. The Atrium Lobby Lounge features a delightful piano bar, Monday through Friday. Trophies sports bar has a 60's flair with entertainment seven days a week.
Rates: Single/Double $155

26. RITZ CARLTON
This AAA Five Diamond property is ranked in the top 20 U.S. hotels by Conde Nast Traveler and Zagat. The hotel is convenient to Philadelphia's business, retail, cultural, and family-oriented attractions. It offers 24-hour room service, fitness center, massage services and valet parking. The Club level features key-only access and a private lounge and concierge. The Dining Room, The Grill, and The Lobby Lounge are noted for outstanding service and cuisine.
Rates: Single/Double $182

27. SHERATON SOCIETY HILL
The newly renovated Sheraton Society Hill is located in the heart of "America's most historic square mile." Guests can enjoy complimentary use of the health club complete with pool, sauna, and top-of-the-line exercise equipment. LaFidley's Bistro American is open seven days a week for breakfast, lunch, and dinner. The atrium courtyard serves daily continental breakfast, lunch, and cocktails. The Wooden Nickel Pub is also open nightly.
Rates: Single $177 Double $197

28. SHERATON UNIVERSITY CITY
Adjacent to the University of Pennsylvania and Drexel University, this hotel has covered parking, restaurant, deli, lounge, room service, gift shop, and remote TV with Showtime, ESPN, and CNN. The Club floor offers complimentary continental breakfast and afternoon hors d'oeuvres.
Rates: Single/Double $134

29. THE WARWICK
The Warwick, Philadelphia's luxury boutique hotel, boasts a premier location for entertainment and business. Nearby are many fine shops, highly acclaimed restaurants, theaters, museums, and galleries. Enjoy casual but elegant dining in Mia's Restaurant and Mezzano Bar, formal dining in the Prime Rib, or visit Capriccio's Coffee Shop for cappuccino and pastries.
Rates: Single $146 Double $156

30. WESTIN SUITES AIRPORT
The Westin Suites is located just 5 minutes from the Philadelphia International Airport and 15 minutes from the Philadelphia Convention Center. We offer complimentary parking and a free shuttle to and from the airport. This all-suite atrium style hotel offers a newly renovated health facility with an indoor and outdoor pool, Jacuzzi, sauna, steam room, and exercise room. We also feature a choice of restaurants and a lounge that features world class cocktails and micro brews. We even have an Express Car Rental desk for your convenience. The Westin Suites is not only all-suite, but all-service.
Rates: Single/Double $129

31. WINDSOR
The Windsor is located at 17th and the Parkway. The Windsor commands a spectacular view of the fountains and museums for which Philadelphia is famous. The hotel is surrounded by legendary cultural and historic attractions, and Philadelphia's greatest concentration of fine restaurants, specialty stores, and night spots. The hotel features a rooftop swimming pool, fitness center, panoramic balcony views, complimentary continental breakfast, valet dry cleaners, full service beauty salon, cable TV, on-site restaurant, concierge, and instant phone service.
Rates: Single/Double $125

32. WYNDHAM FRANKLIN PLAZA
Amid historical and cultural sites, just steps away from the Ben Franklin Parkway museums and the Pennsylvania Convention Center, the hotel is adjacent to I-676 with easy access to I-95 and the New Jersey Turnpike. Facilities include indoor pool, sauna, and whirlpool at the private health club. Underground parking is available.
Rates: Single $169 Double $189
AMERICAN ASSOCIATION FOR CANCER RESEARCH

1999 AACR YOUNG INVESTIGATOR AWARDS
To Support Attendance at the AACR Annual Meeting

AACR Young Investigator Awards support the attendance of medical and graduate students, physicians-in-training, and postdoctoral fellows at the AACR Annual Meeting. Awards are presented to young scientists who are presenters of abstracts that have been highly rated by the AACR Annual Meeting Program Committee. Deadline for submission of abstracts is November 6, 1998. Federal government employees are eligible for AACR Young Investigator Awards, but employees of private industry are not. AACR Young Investigator Awards are generously sponsored by: Amgen, Inc., ACR, Bristol-Myers Squibb Oncology, Genetics Institute, Pharmacia & Upjohn, Inc., PharMingen, among others.

Special eligibility restrictions or application procedures apply to the following Young Investigator Awards:

AACR Gerald B. Grinney Memorial Young Investigator Award honors the research accomplishments of the late Dr. Gerald B. Grinney. The award is presented to a young scientist submitting an abstract in the field of preclinical science. Deadline for submission of abstracts is November 6, 1998.

AACR-AFLAC Scholar Awards support the travel and subsistence expenses of AACR Associate Members who are presenters of highly rated abstracts at AACR’s Annual Meeting. Candidates must be AACR Associate Members or submit an Associate Member application no later than the abstract submission deadline of November 6, 1998. These awards are sponsored by AFLAC, Inc., as part of its support of AACR’s Associate Member program.

AACR-ITO EN, Ltd. Young Investigator Awards for Asian Scientists are awarded to young researchers who are presenters of highly rated abstracts and who will be traveling to the Annual Meeting from throughout Asia. Deadline for submission of abstracts is November 6, 1998.

AACR Minority Scholar Awards support attendance at the Annual Meeting and AACR Special Conferences through the Comprehensive Minority Biomedical Program of the National Cancer Institute (NCI). Young scientists from minority groups considered underrepresented in cancer research by NCI are eligible for these awards, i.e., African Americans, Hispanic Americans, Native Americans, Native Pacific Islanders, and Alaskan Americans. A separate application form is required and can be obtained by contacting the AACR office. The application deadline is December 4, 1998.

Women In Cancer Research Brigid G. Leventhal Scholar Awards are for young investigators who are presenters of highly rated abstracts at the AACR Annual Meeting. A separate application form is required and can be obtained by contacting the AACR office. The awards are sponsored by Women In Cancer Research, an adjunct organization of AACR. The application deadline is December 4, 1998.

American Association For Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9372
E-mail: horst@aacr.org
AACR FORTHCOMING SCIENTIFIC CONFERENCES

OCTOBER 14-18, 1998
Gene Regulation and Cancer
(10th Anniversary of the AACR Special Conferences)
Chairpersons: Phillip A. Sharp, Cambridge, MA; Jacqueline A. Lees; Cambridge, MA; and Steven L. McKnight, Dallas, TX
The Homestead, Hot Springs, VA

NOVEMBER 11-15, 1998
Endogenous Sources of Mutations
Chairpersons: Lawrence J. Marnett, Nashville, TN; James A. Swenberg, Chapel Hill, NC; and Tomas Lindahl, Herts, England
Sanibel Harbour Resort and Spa, Ft. Myers, FL

DECEMBER 2-6, 1998
New Research Approaches to the Prevention and Cure of Prostate Cancer
Chairpersons: Jonathan W. Simons, Baltimore, MD, and Kenneth J. Pienta, Ann Arbor, MI
Hyatt Grand Champions Resort, Indian Wells (Palm Springs), CA

JANUARY 8-12, 1999
The Steroid Receptor Superfamily
Chairpersons: Michael G. Rosenfeld, La Jolla, CA, and Christopher K. Glass, La Jolla, CA
Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

JANUARY 31-FEBRUARY 5, 1999
Cancer Biology and the Mutant Mouse: New Methods, New Models, New Insights
Chairpersons: Tyler Jacks, Cambridge, MA, and Ronald A. DePinho, Boston, MA
Keystone Resort, Keystone, CO

MARCH 4-8, 1999
Molecular Determinants of Sensitivity to Antitumor Agents
Chairpersons: Michael B. Kastan, Memphis, TN, and I. David Goldman, Bronx, NY
Whistler Resort and Conference Centre, Whistler, British Columbia, Canada

SEPTEMBER 22-26, 1999
Molecular Aspects of Metastasis
Chairperson: Ruth J. Muschel, Philadelphia, PA; Additional Chairperson to be Announced
Snowmass Village Resort, Snowmass, CO

OCTOBER 6-10, 1999
The Molecular and Genetic Basis of Chemoprevention and Early Detection of Cancer
Chairpersons: David Sidransky, Baltimore, MD, and Frank L. Meyskens, Jr., Irvine, CA
Sheraton Bal Harbour Resort, Bal Harbour, FL

AACR members will receive brochures on the above conferences as soon as they are available.
Nonmembers should call or write: American Association for Cancer Research Public Ledger Building, Suite 826 150 South Independence Mall West Philadelphia, PA 19106-3483 215-440-9300 • 215-440-9313 (FAX) E-Mail: meetings@aacr.org

For regular updates to this list visit the AACR's Website, http://www.aacr.org
Advance Registration

FREQUENTLY ASKED QUESTIONS

1. What is the deadline for submitting my registration form?

There are multiple deadlines: if you register by December 1 you will pay the low "early bird" registration fee. If you register after December 1 but on or before February 1 you will pay the "advance registration" fee. From February 1 to February 22 you may still register by mail or fax but you must pay the on-site registration fee.

2. What if I don't register by February 22?

Registration forms received in the AACR office after February 22 will not be processed. However, you may register on-site at the Pennsylvania Convention Center in Philadelphia. Registration hours will be 9:00 a.m. to 8:00 p.m. on April 10; 6:30 a.m. to 4:00 p.m. on April 11, 12, and 13; and 6:30 a.m. to 2:00 p.m. on April 14.

3. I am a postdoctoral fellow. May I register at the student rate?

No, you must pay the nonmember rate unless you are or become an Associate Member of AACR (see #4 below).

4. I am a predoctoral student, postdoctoral fellow, or physician-in-training, and I want to become an Associate Member and pay the Associate Member registration fee. What must I do?

You may submit an application for Associate Membership either before or with your Annual Meeting Registration Form, but both must be submitted no later than February 15, 1999, as review of the Associate Member application may delay processing of registration. You may register at the Associate Member rate on the assumption that your application will be accepted; if it is not accepted we will notify you, and you will be required to register at the nonmember rate.

5. I am not currently an AACR member but I have applied or will apply for Active or Corresponding Membership by the September 1, 1998, or January 1, 1999, deadlines. Which registration fee applies?

You must pay the nonmember registration fee. However, when you are officially notified of your election to AACR Membership, you may contact the AACR Office and receive a refund of the difference between the member and nonmember fees.

6. What is your refund policy?

Refunds on registration fees will be granted on written request received in the AACR Office by March 26, 1999. Requests received after this date will not be honored. Receipts and badges (if they have been mailed) must be returned to the AACR Office with the refund request. A cancellation fee of $35 will be deducted from all refunds to cover administrative costs. Copies of the Proceedings may not be returned; an additional $45 will be deducted from the refunds of nonmembers to cover the cost of the Proceedings.

7. How do I receive my Annual Meeting Program and Proceedings?

AACR Members. All AACR members in North America whose 1999 dues are fully paid by February 1, 1999, will automatically receive a copy of the Program and Proceedings prior to the Annual Meeting. AACR members overseas who have paid their 1999 dues by February 1, 1999, will also automatically receive a copy of the Program and Proceedings; however, the receipt of these issues prior to the Annual Meeting is not guaranteed.

Members outside North America who wish to ensure that they receive the Program and Proceedings prior to the annual meeting should check the "Optional Overseas Surcharge" box on the registration form; for an additional fee of $25 the Program and Proceedings will be sent via airmail. This service is not available after February 1, 1999. Please note that AACR members who have not paid their 1999 dues will not be sent a Program and Proceedings and will not be allowed to register for the Annual Meeting at the member rate.

Nonmembers. Nonmembers in North America who register by February 1 will receive a Program and Proceedings prior to the Annual Meeting. Nonmembers who are overseas and wish to ensure that they receive the Program and Proceedings prior to the Annual Meeting may check the "Optional Overseas Surcharge" box on the registration form; for an additional fee of $25 the Program and Proceedings will be sent via airmail. This service is not available after February 1, 1999.

Additional copies of the AACR Proceedings are available for sale from the AACR Office. Fax requests to 215-440-7228.

8. Are there special requirements that nonmember predoctoral students must fulfill in order to register at the predoctoral student rate?

In order to register at the predoctoral student rate, students must complete the "Nonmember Predoctoral Student Certification" section of the registration form, which requires a signature of the registrar, dean, or department head confirming status. Predoctoral student registration forms that do not have this section completed will not be processed. Those wishing to register in Philadelphia at the predoctoral student rate must bring a similar statement on official letterhead in order to register on site at the student rate.

Note: If you have registered at any member rate and have not paid your 1999 dues by February 22, 1999, you will receive an invoice for the difference between the registration fee you paid and the appropriate nonmember rate.
AMERICAN ASSOCIATION FOR CANCER RESEARCH 90TH ANNUAL MEETING
Philadelphia, Pennsylvania • April 10-14, 1999

REGISTRATION FORM

Deadlines:
• December 1, 1998 for low "early bird" rates and to ensure receipt of meeting materials by mail in March
• February 1, 1999 for reduced rates and to ensure receipt of meeting materials by mail in March
• February 15, 1999 for application for Associate Membership in order to register at member rate
• February 22, 1999 for all registration by mail or fax (registration forms received after this date will not be accepted)
• March 26, 1999 to cancel registration and receive refund less cancellation fee

1. NAME AND ADDRESS INFORMATION (please print or type)

First Name/Middle Initial
Are You an AACR Member? Yes  □  No  □
Last Name Membership # ___________________  □  No
Title/Department
Institution
Street, Building, or Post Office Box
City State or Province Zip/Postal Code Country (if not U.S.)
Telephone  Fax
E-Mail

Check this box if you require special accommodations to fully participate in the meeting.
Describe briefly: ____________________________

2. REGISTRATION RATES

<table>
<thead>
<tr>
<th>Active/Corresponding Member</th>
<th>December 1</th>
<th>December 2-February 1</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$175</td>
<td>$205</td>
<td>$250</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nonmember (includes copy of AACR Proceedings)</th>
<th>December 1</th>
<th>December 2-February 1</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$350</td>
<td>$395</td>
<td>$450</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Emeritus Member</th>
<th>December 1</th>
<th>December 2-February 1</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$60</td>
<td>$60</td>
<td>$60</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Associate Member</th>
<th>December 1</th>
<th>December 2-February 1</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$95</td>
<td>$105</td>
<td>$125</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nonmember Predoctoral Student (does not include AACR Proceedings)</th>
<th>December 1</th>
<th>December 2-February 1</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$125</td>
<td>$135</td>
<td>$155</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nonmember Predoctoral Student (includes copy of AACR Proceedings)</th>
<th>December 1</th>
<th>December 2-February 1</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$170</td>
<td>$180</td>
<td>$200</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Honorary Member</th>
<th>December 1</th>
<th>December 2-February 1</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Optional Overseas Surcharge</th>
<th>December 1</th>
<th>December 2-February 1</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25</td>
<td>$25</td>
<td>N.A.</td>
<td></td>
</tr>
</tbody>
</table>

TOTAL ENCLODED OR CHARGED $ _______ $ _______ $ _______

3. METHOD OF PAYMENT

☐ Check or money order enclosed, payable to American Association for Cancer Research, in U.S. currency, drawn on a U.S. bank.

☐ VISA  ☐ MasterCard  ☐ American Express  ☐ Eurocard

Card Number Exp. Date: ___________________  ____________

Signature of cardholder ____________________________

4. ADDITIONAL REGISTRANT INFORMATION

Primary Field of Research (Please Circle Only One):
1. Biochemistry/Biophysics
2. Carcinogenesis
3. Cellular Biology and Genetics
4. Clinical Investigations
5. Endocrinology/Signal Transduction
6. Epidemiology
7. Experimental Therapeutics
8. Immunology
9. Molecular Biology and Genetics
10. Prevention
11. Radiobiology/Radiation Oncology
12. Virology
13. Other (please specify): ____________________________

ARE YOU THE PRESENTER OF AN ABSTRACT SUBMITTED FOR THE 1999 ANNUAL MEETING? Yes  ☐  No  □

☐ Check this box if you are a high school or undergraduate student. This information will be used for the organization of a special educational event during the Annual Meeting for students interested in pursuing careers in science.

5. NONMEMBER PREDOCTORAL STUDENT SECTION

This section must be completed if you are a nonmember predoctoral student. Forms without certification will not be processed.

NONMEMBER PREDOCTORAL STUDENT CERTIFICATION
"I certify that the above named student is presently enrolled at this University and working toward a doctoral degree in a field related to cancer research."

SIGNATURE (Registrar, Dean or Dept. Head)

TITLE ____________________________

UNIVERSITY ____________________________

6. RETURN TO:

Annual Meeting Registration
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483

Fax: 215-440-7228

NOTE: THE INFORMATION ON THE REVERSE SIDE OF THIS PAGE IS CONSIDERED PART OF THE REGISTRATION FORM FORMS WITHOUT PAYMENT WILL NOT BE PROCESSED
1999 PROGRAM COMMITTEE MEMBERS

CELL AND TUMOR BIOLOGY SUBCOMMITTEES

Cell Growth Signaling Pathways: Cell Biology Aspects
Yoon Sang Cho-Chung, Chairperson
Matthew J. Ellis
Susan Jaken
Robert A. Phillips

Cell Death Signaling
Alan R. Eastman, Co-Chairperson
Douglas R. Green, Co-Chairperson
Arnold H. Greenberg
W. Stratford May
Timothy J. McDonnell

Tumor Progression, Invasion and Metastasis
Danny R. Welch, Chairperson
Mary J. C. Hendrix
Janet E. Price
Joy L. Ware

Host-Tumor Interactions:
Angiogenesis and Microcirculation
Robert Radinsky, Chairperson
Lee M. Ellis
Tona M. Gilmer
Carrie W. Rinker-Schaeffer
Bruce R. Zetter

MOLECULAR BIOLOGY SUBCOMMITTEES

Cancer Genetics I: New Loci and Mechanisms of Genomic Alterations
Olli-P. Kallioniemi, Chairperson
Ake Borg
Kay Huebner
Jae-Galb Park

Cancer Genetics II: Tumor Suppressor Genes - Structure and Function
Graham Casey, Chairperson
Guillermma Loranzo
Bernard E. Weistman
Roger W. Wiseman
Jun Yokota

Cancer Genetics III: Human and Retroviral Oncogenes - Structure and Function/Viral Oncogenesis
Takis S. Papas, Chairperson
John M. Lehman
Vicente Notario
Bettie M. Steinberg
Harald zur Hausen

Gene Expression and Epigenetic Regulation
James G. Herman, Chairperson
Steven J. Kuerbitz
Russell O. Pieper
Paula M. Vertino

Gene Regulation and Transcriptional Control of the Cancer Phenotype
Bryan R. G. Williams, Chairperson
Frederic G. Barr
Paul S. Meltzer
Linda J. Z. Penn

Cell Cycle
Jean Y. J. Wang, Chairperson
Shi Huang
Jacqueline A. Lees
Elizabeth S. Woo

CARCINOGENESIS SUBCOMMITTEES

Biomarkers, Premalignant Lesions, and Risk Assessment
Walter N. Hittelman, Chairperson
William E. Grizzle
Fred F. Kadlubar
Thomas W. Kensler
Additional member to be appointed

Molecular Carcinogenesis: Metabolism, DNA Lesions, Mutagenesis and DNA Repair
Peter G. Shields, Chairperson
Vilhelm A. Bohr
F. Peter Guengerich
Steven R. Paterno
Additional member to be appointed

Promotion and Progression
Stuart H. Yurpa, Chairperson
Diane F. Birt
Eileen A. Friedman
Adam B. Glick

Epidemiology SUBCOMMITTEES

Analytical Epidemiology in Populations
David J. Hunter, Chairperson
Wong Ho Chow
Nubia Muñoz
Julie A. Ross

Molecular and Genetic Epidemiology
Neil E. Caporaso, Chairperson
Christine B. Ambrosone
Kenneth Offit
Margaret R. Spitz

Prevention/Basic Science and Clinical Studies SUBCOMMITTEE

Preclinical Prevention Studies: Markers and Mechanisms
Michael N. Gould, Chairperson
Pamela L. Crowell
Ronald A. Lubet
Bandaru Reddy
Gary D. Stoner

Clinical Prevention Studies
Barnett S. Kramer, Chairperson
Steven E. Benner
Ewart T. Hawk
Scott M. Lippman
Gordon McVie

Clinical Research SUBCOMMITTEES

Phase I-III Clinical Trials
David R. Spriggs, Co-Chairperson
James L. Abbuzzese, Co-Chairperson
Daniel F. Hayes
David Khayat
Makoto Ogawa
Raphael E. Pollock
George Wilding

Organ-Site Specific Studies I: Preclinical Research - Tumor Biology/Translational Research
Kathleen R. Cho, Co-Chairperson
Ruth J. Muschel, Co-Chairperson
Candace L. Gladson

Lora Hedrick-Ellesson
William G. Nelson
Chan H. Park
Ramon A. Parsons

Organ-Site Specific Studies II: Preclinical Research - Experimental Therapeutics
Michael John Hawkins, Co-Chairperson
Robert F. Ozols, Co-Chairperson
Robert Clarke
Robert B. Dickson
Herbert M. Pinedo
Nagahiro Saito
Mario Sznol

Clinical Pharmacology/Modality-Based Clinical Research
Ross C. Donohue, Chairperson
Karen S. H. Antman
George J. Boul
Michael A. Caligiuri
Roy B. Jones
Paul S. Wissel

Molecular Biology/Molecular Oncology in the Clinic
L. Michael Glodé, Chairperson
Carlos Gordon-Cardo
Ethan Dmitrovsky
Madeleine Kane
Homer L. Pearce

Supportive Care, Psychosocial Aspects of Cancer, and Survivorship
Jimmie C. Holland, Chairperson
Harvey J. Cohen
Additional member to be appointed

Endocrinology/Preclinical and Clinical SUBCOMMITTEES

Molecular and Preclinical Endocrinology: Receptors and Signal Transduction
Reuben Lotan, Co-Chairperson
Neal Rosen, Co-Chairperson
Anjum Jetten
Candace S. Johnson

Clinical Endocrinology
Samuel A. Wells, Jr., Chairperson
Koaru Abe
Ian D. Hay
Barry D. Nelkin

Immunology/Preclinical and Clinical SUBCOMMITTEES

Tumor Immunobiology: Experimental and Preclinical
David Paul Carbone, Co-Chairperson
Dorothée Herlyn, Co-Chairperson
Paulette S. Gray
Ellen S. Vitetta
Louis M. Weiner
Additional member to be appointed

Clinical Immunology: Biological Therapy
David Ross Parkinson, Co-Chairperson
Razelle Kurzrock, Co-Chairperson
Philip J. Browning
Sunil Kumar Chatterjee
Alan N. Houghton

Pharmacology and Experimental Therapeutics SUBCOMMITTEES

Drug Discovery, Design, Screening, and Delivery Systems
Randall K. Johnson, Co-Chairperson
Roman Perez-Soler, Co-Chairperson
Bruce C. Baguley
Thomas G. Burke
Anna Maria Casazza
Additional member to be appointed

Molecular Approaches
William K. Plunkett, Co-Chairperson
Janet A. Houghton, Co-Chairperson
O. Michael Colvin
William S. Dalton
Patrick M. O’Connor

Drug Resistance I: Multidrug Resistance
Susan E. Kane, Chairperson
James M. Groop
Giuseppe Giaccione
William N. Hait

Drug Resistance II
Igor B. Roninson, Chairperson
Roger G. Deely
Scott W. Lowe
Jeffrey A. Moscow

Pharmacology and Preclinical Toxicology
Michaele Christian, Chairperson
Matthew M. Ames
Jerry M. Collins
Additional member to be appointed

Therapeutic Agents I: Small Molecule Approaches
Alexander W. Wood, Chairperson
Ivan D. Horak, Co-Chairperson
Carlos Arteaga
Gordon B. Mills
Allen I. Oliff

Therapeutic Agents II: Biologic Approaches
Eugenie S. Kleinerman, Chairperson
Adrian Harris
Paul Sondel
Additional member to be appointed

Experimental Gene Therapy
Esther H. Chang, Chairperson
David T. Curiel
Mien-Chie Hung
Additional member to be appointed

Topoisomerases, Other DNA-Reactive Agents, and Tubulin Agents
Mary-Ann Bjornst, Chairperson
Neil W. Gibson
Neil Osheroff
Eric H. Rubin

Radiobiology/Radiation Oncology SUBCOMMITTEE

Luka Milas, Co-Chairperson
Zvi Y. Fuks, Co-Chairperson
William H. McBride
Mark W. Dewhirst
H. Rodney Wickens
Additional member to be appointed
Visit the AACR Website!

www.aacr.org

Turn to our website to find:

☐ AACR Scientific Meetings Schedule
☐ 1998 Annual Meeting Abstracts
☐ Abstracts of Articles from AACR Journals
☐ Instructions for Authors
☐ Information about AACR Research Fellowships and Young Investigator Awards
☐ The latest AACR Newsletter, and more!

AMERICAN ASSOCIATION FOR CANCER RESEARCH
Guidelines for Submitting Disks
to
American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite                     WordPerfect (DOS, Windows, and Macintosh)
Microsoft Word (DOS, Windows, and Macintosh)  XyWrite (DOS and Windows)

Also acceptable:

Ability                      Mass 11                      SoloWriter
AmiPro                       MS Windows Write              Sprint
A*, S-TeX                    MS Works                      Stx
Appleworks                   MS Works WP Mac                 SunWrite
ArborTeX                     Multimate                     Symphony
ArborText                    Multimate Advantage           TEX
ClarisWorks WP               Nibia                        TeX78
CPT 8000                     Nisus (to ASCII file)          Text EXecutive
CTOS                         Notewriter                    Textures
Diablo                       Obun                         Total Word
DisplayWrite                 OfficeWriter                  Troff
Duet                         PC Write                      μTeX
Einstein                     PFS First Choice              Volkswriter
Enable                       Professional Write            VuWriter
EXP                          Q&A Write                     Wang OIS
Final Word                   Quark XPress                 Wang WPS
FullWrite                    RagTime MS Works              Wang Writer
GemWord Plus                 (to ASCII file)                Window Works
IBM Writing Assistant       Rich Text Format              Windows Write
Interleaf                    RSG (to ASCII file)           WiziWord
LaTeX                        Signature                    Wordstar
Latex                        SLiTEx                       Wordstar 2000
Leading Edge                 SmartWhere                   WriteNow
Lotus Manuscript             SmartWrite II                Xerox
Lotus Write

Software packages that we are unable to translate:

FrameMaker                  Ready, Set, Go
PageMaker                    Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ________________________________
Name of computer used (e.g., IBM/PS2): ______________________________
Operating system and version (e.g., DOS 3.3): ________________________
Word processing program and version (e.g., WordPerfect 5.0): ____________
[See reverse for acceptable programs.]

Manuscript number: ________________________________________________
First author: ______________________________________________________
Corresponding author (if different from first author): ____________________
Telephone/FAX numbers: ____________________________________________

This form (both sides) may be reproduced.
FDA-NCI
Food and Drug Administration - National Cancer Institute

Workshop on Tumor Vaccines
Masur Auditorium, National Institutes of Health
December 10, 1998 - 7:30 a.m. to 5:00 p.m.
December 11, 1998 - 8:00 a.m. to 5:30 p.m.

The purpose of the meeting is to discuss the current state of tumor vaccine development and characterization and potency tests for various classes of cell vaccines. Other major discussions will include the detection of tumor cell contamination in immunotherapy products and immunological assessments in early clinical trials.

Session I: Regulatory Considerations in Tumor Vaccines
Session II: Phenotypic and Functional Characterization of Dendritic Cells (DC) or Other Antigen Presenting Cells (APC)
Session III: Autologous and Allogeneic Tumor Cells as Tumor Vaccines
Session IV: Preclinical Strategies and Immunological Assessments in Early Clinical Trials of Tumor Vaccines
Session V: Detection and Characterization of Tumor Cells in Cellular Vaccines

AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 13,500 scientists and physicians involved in all aspects of basic, clinical, and translational cancer research. Members of the AACR enjoy:

- subscriptions to Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at reduced member rates
- reduced registration rates at the AACR Annual Meeting, Special Conferences, and International Meetings
- Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include:

- Session on Career Development at Annual Meeting
- Mentorship Program
- Travel Awards to Scientific Conferences

American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
Fax: (215) 440-9313
The National Cancer Institute Announces

cancerTrials™

http://cancertrials.nci.nih.gov

Featuring Online

- The latest news in cancer research & trials
- Step-by-step guide to finding clinical trials
- Easy access to all clinical trials resources from NCI

Visit us at http://cancertrials.nci.nih.gov
Your Link to the Latest Treatment Strategies

Clinical Cancer Research:
Your source for:
- Reports of clinical trials
  Descriptions of the latest treatment strategies being employed worldwide
- Translational studies
  Critical research bridging the lab and the clinic
- Minireviews
  Concise, informative summaries of broad areas of oncology
- Meeting reports, and more
  Reports from scientific meetings, plus special lectures, letters to the editor, and more

Editor-in-Chief:
John Mendelsohn, M.D.
UT M.D. Anderson Cancer Center

SUBSCRIBE TODAY!
Call 1-800-633-4931 or (205) 995-1567 or return the coupon below.

Yes! I’d like to subscribe!
Clinical Cancer Research
Vol. 4, 1998, 12 issues, ISSN 1078-0432

AACR Members:
Contact AACR for special subscription rates

Individual (For individual use only; not for use in a library)
☐ $120
☐ $120 should be added for delivery outside the U.S.

Institutional (Available only as a combined subscription with Cancer Research)
☐ $795
☐ $130 should be added for delivery outside the U.S.
Canada: Add 7% GST; MD: Add State Sales Tax

Name

Address

City State Postal Code

Country

Method of Payment
☐ Enclosed check or money order in U.S. dollars drawn on U.S. bank. Payable to American Association for Cancer Research.
☐ Institutional purchase order # __________ is enclosed.
☐ Please charge my ☐ MasterCard ☐ VISA ☐ American Express

Account Name

Account Number

Expiration Date

Signature

Mail coupon to:
Clinical Cancer Research, Subscription Office,
P.O. Box 11806, Birmingham, AL 35202, USA.
If paying by credit card, fax form to: (205) 995-1588.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

New Research Approaches in the Prevention and Cure of Prostate Cancer
December 2-6, 1998
Hyatt Grand Champions Resort
Indian Wells (Palm Springs), CA

Supported by Major Educational Grants from
Bristol-Myers Squibb Oncology and from
Beckman Coulter, Inc.

CONFERENCE CO-CHAIRPERSONS
Jonathan W. Simons / Baltimore, MD
Kenneth J. Pienta / Ann Arbor, MI

CONFERENCE PROGRAM

Keynote Addresses
Andy Grove / Santa Clara, CA
Leroy E. Hood / Seattle, WA
Donald S. Coffey / Baltimore, MD

Heredity and Environment
Elaine A. Ostrander / Seattle, WA
William B. Isaacs / Baltimore, MD
William G. Nelson / Baltimore, MD
Theodore L. DeWeese / Baltimore, MD
Otila W. Brawley / Bethesda, MD

Local Control of Clinical Prostate Cancer
Jeffrey D. Forman / Detroit, MI
Curtis A. Pettaway / Houston, TX

Molecular Pathology
Lance A. Liotta / Bethesda, MD
Jill A. Macoska / Ann Arbor, MI
Robert E. Reiter / Los Angeles, CA

Hormones and Hormone Therapy
Evelyn R. Barrack / Baltimore, MD
Ronald M. Evans / La Jolla, CA
Martin E. Gleave / Vancouver, BC, Canada
June M. Chan / Boston, MA

Prostate Cancer Tumor Biology
Carrie W. Rinker-Schaeffer / Chicago, IL
Norman M. Greenberg / Houston, TX
Robert S. Kerbel / Toronto, Ontario, Canada

New Therapeutic Initiatives for Advanced Disease
Stuart Holden / Santa Monica, CA
Robert E. Wittes / Bethesda, MD
Erkki Ruoslahti / La Jolla, CA
Jonathan W. Simons / Baltimore, MD
Neal Rosen / New York, NY

Growth Factors
Wallace L. McKeelhan / Houston, TX
Michael O’Reilly / Boston, MA
Robert H. Getzenberg / Pittsburgh, PA
Ronald A. Morton, Jr. / Houston, TX

Novel Therapeutic Strategies
Kenneth J. Pienta / Ann Arbor, MI
Gerald P. Murphy / Seattle, WA
Martin G. Senda / Ann Arbor, MI
Alan W. Partin / Baltimore, MD

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: meetings@aacr.org
Website: http://www.aacr.org